https://trial.medpath.com/news/cf6bb2aebfeaff71/iran-becomes-first-asian-country-to-develop-electrochemotherapy-cancer-treatment-technology 2025-05-26T16:37:46+00:00 hourly 0.9 https://trial.medpath.com/news/17bbb4418f8a5e48/prestige-biopharma-will-join-hands-with-global-pharmaceutical-company-teva-to-launch 2025-05-26T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/a4dd0855ffef3681/cornerstone-robotics-secures-70m-series-c-to-challenge-da-vinci-s-surgical-robot-dominance 2025-05-26T16:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/10ebd029ce7be508/medipharm-labs-begins-production-of-cannabis-metered-dose-inhalers-for-european-market-expansion 2025-05-26T16:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/95ba663870ed07be/avance-clinical-positions-australia-as-strategic-alternative-for-us-biotech-clinical-trials-amid-regulatory-uncertainty 2025-05-26T16:15:49+00:00 hourly 0.9 https://trial.medpath.com/news/b401206e3c2eb772/jak-inhibitors-transform-polycythemia-vera-treatment-as-novel-therapies-emerge 2025-05-26T16:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/4ab595a789ffe3fe/huonslab-completes-enrollment-in-phase-1-trial-for-recombinant-hyaluronidase-eyes-2025-regulatory-filing 2025-05-26T16:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/1c9695455f7bc0f2/madras-diabetes-research-foundation-partners-with-russia-s-almazov-centre-for-ai-driven-diabetes-research 2025-05-26T12:45:37+00:00 hourly 0.9 https://trial.medpath.com/news/1e9db2ba07f1077a/biotalys-appoints-luc-van-fraeyenhoven-as-cfo-to-lead-financial-strategy-during-product-commercialization-phase 2025-05-26T11:44:40+00:00 hourly 0.9 https://trial.medpath.com/news/acac1c6c959787b1/brandon-capital-opens-second-5m-funding-round-for-dementia-innovation-program 2025-05-26T08:46:27+00:00 hourly 0.9 https://trial.medpath.com/news/441bd9d7c160d8b4/insilico-medicine-predicts-first-ai-designed-drugs-to-reach-market-by-2030 2025-05-26T08:46:22+00:00 hourly 0.9 https://trial.medpath.com/news/18f4f38bc4d5a38b/seqone-genomics-secures-eur20-million-to-accelerate-ai-powered-ngs-platform-for-personalized-medicine 2025-05-26T08:46:03+00:00 hourly 0.9 https://trial.medpath.com/news/2f636d16f1f88f99/lupin-partners-with-steincares-to-commercialize-ranibizumab-biosimilar-across-latin-america 2025-05-26T08:14:48+00:00 hourly 0.9 https://trial.medpath.com/news/29739d11ec2d0339/sernova-biotherapeutics-chairman-ross-haghighat-resigns-as-company-advances-type-1-diabetes-cell-therapy 2025-05-26T07:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/8acb39c5db0743da/abbisko-s-fgfr4-inhibitor-irpagratinib-receives-china-s-breakthrough-therapy-designation-for-hepatocellular-carcinoma 2025-05-26T05:16:24+00:00 hourly 0.9 https://trial.medpath.com/news/173e5729f6c87a6d/recce-pharmaceuticals-secures-strategic-china-patent-to-expand-asian-market-presence 2025-05-26T04:48:09+00:00 hourly 0.9 https://trial.medpath.com/news/b33b8b92a83de6b0/predictive-models-show-high-accuracy-in-identifying-severe-pediatric-pneumonia-cases 2025-05-26T04:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/ab7f4d25c291b4e2/immutep-s-eftilagimod-alpha-combination-meets-primary-endpoint-in-phase-ii-soft-tissue-sarcoma-trial 2025-05-26T00:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/6cbcf18cd98275df/cuban-biotech-company-labiofam-s-biorat-rodenticide-shows-success-in-barbados-pilot-study 2025-05-25T20:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/e820bbd22e034b27/grandpharma-s-gpn01768-receives-macao-approval-for-demodex-blepharitis-treatment 2025-05-25T20:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/f7adf738f50dd376/genetic-testing-revolutionizes-breast-cancer-treatment-two-week-test-predicts-relapse-risk-and-spares-patients-from-unnecessary-chemotherapy 2025-05-25T16:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/ab412fd4efa348c7/nuvalent-to-present-first-clinical-data-for-next-generation-alk-inhibitor-nvl-655-at-aacr-nci-eortc-symposium 2025-05-25T16:37:26+00:00 hourly 0.9 https://trial.medpath.com/news/f36d8a3c937d8849/cdsco-panel-approves-label-updates-for-sanofi-s-rare-disease-therapies-fabrazyme-and-aldurazyme 2025-05-25T12:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/60ad76d9fddf947b/proteomics-international-s-promarkerendo-blood-test-achieves-90-accuracy-in-early-endometriosis-detection 2025-05-25T11:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/2e19e4501facfbbd/multiple-myeloma-treatment-landscape-shows-promise-with-novel-combination-therapies-in-recent-clinical-trials 2025-05-25T06:36:44+00:00 hourly 0.9 https://trial.medpath.com/news/34fbfee03b01cf67/axle-health-raises-10m-series-a-to-scale-ai-powered-home-healthcare-platform 2025-05-25T04:36:45+00:00 hourly 0.9 https://trial.medpath.com/news/dbaa4082fa0ea72d/pfizer-strikes-6-billion-deal-with-3sbio-as-remegen-raises-hk-796-million-in-premium-placement 2025-05-25T04:36:44+00:00 hourly 0.9 https://trial.medpath.com/news/aba277561926f11c/ruxoprubart-achieves-primary-endpoints-in-phase-2-trial-for-paroxysmal-nocturnal-hemoglobinuria 2025-05-25T03:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/a2673050040c4db7/global-rheumatoid-arthritis-incidence-rises-13-2-over-three-decades-despite-declining-mortality 2025-05-25T02:36:31+00:00 hourly 0.9 https://trial.medpath.com/news/afe34db67ef3b2f8/psma-pet-imaging-transforms-prostate-cancer-management-with-multiple-fda-approved-agents 2025-05-25T02:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/edbc9cda5275d1a8/c-diff-advocates-highlight-critical-role-of-pharmacists-and-public-health-infrastructure-at-national-summit 2025-05-25T02:16:33+00:00 hourly 0.9 https://trial.medpath.com/news/b866f16b288ef336/indian-pharma-companies-advance-semaglutide-development-as-cdsco-approves-clinical-trial-protocols 2025-05-25T00:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/303aec290452a4dd/nyxoah-launches-genio-neurostimulation-therapy-for-sleep-apnea-in-middle-east 2025-05-25T00:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/7b2b112a601565bd/sahpra-approves-first-who-listed-mpox-diagnostic-test-as-south-africa-reports-31-cases 2025-05-25T00:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/422738de832c6ad9/real-world-study-reveals-60-of-eligible-patients-not-receiving-adjuvant-abemaciclib-for-high-risk-early-breast-cancer 2025-05-25T00:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/299e39356083ca4c/exosome-therapeutics-field-advances-toward-clinical-trials-as-industry-prepares-for-regulatory-milestones 2025-05-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3879edb61c7996e8/protein-therapeutics-market-surges-to-400-billion-as-20-new-drugs-gain-approval-in-2023 2025-05-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7b6949ca381fcecb/ku-leuven-researchers-develop-dual-agent-method-to-permanently-silence-hiv-virus 2025-05-24T18:14:51+00:00 hourly 0.9 https://trial.medpath.com/news/9985dfc0087c0732/fda-lifts-clinical-hold-on-allogene-s-allocar-t-studies-after-safety-investigation-clears-manufacturing-process 2025-05-24T16:44:04+00:00 hourly 0.9 https://trial.medpath.com/news/b692b1d91c75b53a/mynd-life-sciences-settles-3-5m-debenture-through-equity-issuance-to-advance-depression-biomarker-development 2025-05-24T16:43:56+00:00 hourly 0.9 https://trial.medpath.com/news/0187842d094da406/philippines-accelerates-african-swine-fever-and-avian-influenza-vaccine-approvals-with-enhanced-da-fda-collaboration 2025-05-24T16:43:19+00:00 hourly 0.9 https://trial.medpath.com/news/0b8e9b9b9d14e583/community-pneumococcal-vaccination-program-reduces-pneumonia-deaths-by-25-in-japanese-elderly-population 2025-05-24T16:43:11+00:00 hourly 0.9 https://trial.medpath.com/news/1c08567301d36ed5/mskai-spine-imaging-software-receives-fda-510-k-clearance-for-lumbar-mri-analysis 2025-05-24T16:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/3705125f88c78e65/moderna-withdraws-covid-19-influenza-combination-vaccine-application-following-fda-data-request 2025-05-24T13:45:12+00:00 hourly 0.9 https://trial.medpath.com/news/247090f1739fdf3e/sana-biotechnology-schedules-june-2025-investor-conference-presentations-to-update-on-engineered-cell-therapy-pipeline 2025-05-24T13:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/dcd2afed4c27971b/hsk21542-demonstrates-superior-efficacy-in-two-phase-3-trials-for-postoperative-pain-management 2025-05-24T12:36:44+00:00 hourly 0.9 https://trial.medpath.com/news/b4f1603e36fca7c9/monteloeder-s-nutroxsun-shows-promise-in-clinical-trial-for-uv-induced-skin-protection 2025-05-24T12:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/5f680144571dee1e/pfizer-s-braftovi-combination-therapy-halves-death-risk-in-braf-mutant-metastatic-colorectal-cancer 2025-05-24T09:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/819a0b910672398b/adm-s-priome-mh-postbiotic-shows-metabolic-benefits-in-canine-clinical-trial 2025-05-24T08:45:11+00:00 hourly 0.9 https://trial.medpath.com/news/f9ff5509b3ccd245/braid-trial-shows-additional-imaging-could-triple-breast-cancer-detection-in-women-with-dense-breasts 2025-05-24T06:45:20+00:00 hourly 0.9 https://trial.medpath.com/news/943d240517caa390/elixir-medical-s-dynamx-bioadaptor-shows-sustained-clinical-benefits-over-drug-eluting-stents-at-three-years 2025-05-24T06:45:10+00:00 hourly 0.9 https://trial.medpath.com/news/5226d2a7dcf625f5/bio-path-holdings-reports-clinical-progress-across-cancer-pipeline-with-promising-patient-responses 2025-05-24T03:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/f284576b855910db/trump-administration-s-maha-report-calls-for-sweeping-reforms-to-address-childhood-health-crisis 2025-05-24T02:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/6f7f971a70091994/hkumed-s-combined-locoregional-immunotherapy-achieves-46-complete-response-rate-in-advanced-liver-cancer 2025-05-24T00:45:57+00:00 hourly 0.9 https://trial.medpath.com/news/21ec2ac8a83bef20/prothena-discontinues-birtamimab-development-after-phase-3-failure-in-al-amyloidosis 2025-05-24T00:44:51+00:00 hourly 0.9 https://trial.medpath.com/news/057a195a7656bf86/enhertu-receives-first-ever-time-limited-reimbursement-for-gastric-cancer-in-canada 2025-05-24T00:44:48+00:00 hourly 0.9 https://trial.medpath.com/news/fec3c1a1f0d7e17f/tandem-diabetes-care-settles-patent-dispute-with-roche-for-36-million 2025-05-24T00:44:31+00:00 hourly 0.9 https://trial.medpath.com/news/9cf7b4b11bc1bb81/tevogen-bio-expands-tvgn-489-pipeline-to-include-patients-65-and-older-targeting-1-billion-launch-year-revenue 2025-05-24T00:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/00a1475ebae05091/caris-life-sciences-files-for-300-million-ipo-to-advance-ai-powered-precision-oncology-platform 2025-05-24T00:16:15+00:00 hourly 0.9 https://trial.medpath.com/news/5ad8ee31638d0fcb/ziftomenib-shows-promise-in-pivotal-komet-001-trial-for-relapsed-refractory-npm1-mutant-aml 2025-05-24T00:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/21f2698910a37544/world-first-octopus-trial-offers-new-hope-for-progressive-multiple-sclerosis-patients 2025-05-24T00:15:52+00:00 hourly 0.9 https://trial.medpath.com/news/cf9b5d460fc38c53/gv20-therapeutics-to-present-ai-designed-immune-checkpoint-inhibitor-data-for-advanced-melanoma-at-asco-2025 2025-05-24T00:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/7df7126af5657dfd/autobahn-therapeutics-abx-002-shows-promising-phase-1-results-for-depression-treatment 2025-05-24T00:15:06+00:00 hourly 0.9 https://trial.medpath.com/news/bc96dc7bb0458061/pharmaceutical-industry-sees-wave-of-board-appointments-as-companies-strengthen-leadership 2025-05-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2992634b9646a004/sun-pharma-invests-25-million-in-pharmazz-expanding-stake-to-22-7-and-securing-key-drug-rights 2025-05-23T21:45:10+00:00 hourly 0.9 https://trial.medpath.com/news/a7e1765d691853a4/real-world-study-reveals-lower-immune-related-adverse-events-in-latin-american-liver-cancer-patients-treated-with-atezolizumab-bevacizumab 2025-05-23T21:45:05+00:00 hourly 0.9 https://trial.medpath.com/news/ef13fd301517a9db/moderna-submits-lp-8-1-targeting-covid-19-vaccine-to-fda-for-2025-2026-season 2025-05-23T20:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/0ff3e1cd583af1f1/lg-chem-s-aveo-pharmaceuticals-sues-hetero-labs-over-kidney-cancer-drug-patent-infringement 2025-05-23T20:36:54+00:00 hourly 0.9 https://trial.medpath.com/news/0d256c5ff073a00d/long-term-study-confirms-rivaroxaban-s-safety-and-efficacy-for-extended-use-in-children-with-venous-thromboembolism 2025-05-23T20:22:24+00:00 hourly 0.9 https://trial.medpath.com/news/c2910da669d2389e/fda-approves-qamzova-china-developed-long-acting-injectable-painkiller-to-combat-opioid-crisis 2025-05-23T20:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/d38a95f5223208ef/enhanced-premedication-protocol-reduces-infusion-reactions-in-nsclc-patients-receiving-amivantamab 2025-05-23T20:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/6be00c2a5b5adcf0/novel-nasal-spray-foralumab-shows-promise-in-reducing-brain-inflammation-in-alzheimer-s-patient 2025-05-23T19:46:33+00:00 hourly 0.9 https://trial.medpath.com/news/0253050df7cb944a/curatis-reveals-corticorelin-as-active-substance-in-c-ptbe-01-with-billion-dollar-market-potential 2025-05-23T19:14:56+00:00 hourly 0.9 https://trial.medpath.com/news/b9c5df45c8103d4a/european-commission-approves-first-mek-inhibitor-for-nf1-associated-plexiform-neurofibromas-in-adults-and-children 2025-05-23T17:17:18+00:00 hourly 0.9 https://trial.medpath.com/news/63f157e6980e23cd/ema-restricts-azithromycin-use-to-combat-rising-antimicrobial-resistance 2025-05-23T16:49:42+00:00 hourly 0.9 https://trial.medpath.com/news/25b863e9f98c68e7/revolutionary-10-minute-technique-loads-mrna-into-exosomes-using-fusogenic-cubosomes 2025-05-23T16:49:35+00:00 hourly 0.9 https://trial.medpath.com/news/72995808291a51cb/researchers-enhance-lentiviral-vector-potency-for-liver-gene-therapy 2025-05-23T16:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/ad0d36a6f275c3bb/northx-biologics-secures-strategic-investment-from-signet-healthcare-partners-to-accelerate-global-expansion 2025-05-23T16:48:41+00:00 hourly 0.9 https://trial.medpath.com/news/76309e49248a488a/revolutionary-blood-test-promises-rapid-diagnosis-for-thousands-of-rare-genetic-diseases-in-children 2025-05-23T16:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/c6ab802a6ba3b72b/merck-defends-current-gardasil-9-dosing-amid-regulatory-discussions-on-single-dose-regimen 2025-05-23T16:48:24+00:00 hourly 0.9 https://trial.medpath.com/news/b64409acb176156a/orion-and-shilpa-medicare-partner-to-bring-recombinant-human-albumin-to-european-market 2025-05-23T16:48:14+00:00 hourly 0.9 https://trial.medpath.com/news/845dd9f9d2f8fe57/fda-sets-october-2025-decision-date-for-xbrane-s-ranibizumab-biosimilar-application 2025-05-23T16:48:05+00:00 hourly 0.9 https://trial.medpath.com/news/e5663a1a00a6aee6/insilico-medicine-develops-ai-designed-enpp1-inhibitor-ism5939-for-cancer-immunotherapy 2025-05-23T16:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/45b0b1019e9da278/texas-a-m-researcher-s-umbilical-cord-cell-therapy-shows-promise-for-als-treatment-in-clinical-trials 2025-05-23T16:09:44+00:00 hourly 0.9 https://trial.medpath.com/news/6608282ac558f526/cinclus-pharma-and-zentiva-form-eur220-million-partnership-for-novel-gerd-treatment-in-europe 2025-05-23T16:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/0b505d46656897ed/fda-approves-phraxis-endoforcetm-connector-advancing-hemodialysis-access-technology 2025-05-23T16:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/b4ef7c9ca126105e/roche-partners-with-broad-clinical-labs-to-advance-sbx-sequencing-for-critically-ill-newborns 2025-05-23T14:46:18+00:00 hourly 0.9 https://trial.medpath.com/news/e2553a3897b30ec9/senti-bio-receives-1m-cirm-milestone-payment-as-senti-202-car-nk-therapy-shows-promising-early-results-in-blood-cancers 2025-05-23T13:39:24+00:00 hourly 0.9 https://trial.medpath.com/news/2f78f2498ff0c06a/mtf-biologics-and-kolosis-bio-introduce-novel-allografts-to-advance-cardiac-surgery-outcomes 2025-05-23T13:12:55+00:00 hourly 0.9 https://trial.medpath.com/news/57db6ac9779b5be3/indoco-remedies-receives-fda-approval-for-generic-allopurinol-tablets-to-treat-high-uric-acid-levels 2025-05-23T12:41:32+00:00 hourly 0.9 https://trial.medpath.com/news/6d820f7f1299ca28/chinese-base-editing-therapy-successfully-cures-thalassemia-in-four-children 2025-05-23T12:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/ac10f2a275c639f4/novartis-invests-in-aging-research-a-550-million-bet-on-the-future-of-drug-development 2025-05-23T12:39:12+00:00 hourly 0.9 https://trial.medpath.com/news/9d62476b404dfc5c/ai-transforms-real-world-data-into-regulatory-grade-evidence-for-ophthalmology-research 2025-05-23T12:39:10+00:00 hourly 0.9 https://trial.medpath.com/news/1c30540c7db7164e/federal-circuit-upholds-patent-invalidation-of-uniqure-s-hemgenix-gene-therapy-in-pfizer-challenge 2025-05-23T11:16:50+00:00 hourly 0.9 https://trial.medpath.com/news/43c1013ae2997ba5/mindhyve-ai-partners-with-islamabad-diagnostic-centre-to-deploy-agi-powered-diagnostic-intelligence-across-pakistan 2025-05-23T10:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/cf2804c95b8141f3/duke-study-shows-enzalutamide-combination-extends-survival-by-30-in-metastatic-prostate-cancer 2025-05-23T09:43:01+00:00 hourly 0.9 https://trial.medpath.com/news/a728854af0d361e1/ulefnersen-shows-unprecedented-recovery-in-young-patients-with-rare-fus-als 2025-05-23T08:46:21+00:00 hourly 0.9 https://trial.medpath.com/news/7af24cb6c5db2392/nykode-therapeutics-presents-promising-immunotherapy-data-for-hpv16-positive-cancer-and-solid-tumors-at-asco-2025 2025-05-23T08:45:31+00:00 hourly 0.9 https://trial.medpath.com/news/bceeb81da768c942/vanda-pharmaceuticals-appeals-to-supreme-court-over-fda-s-fast-track-denial-for-gastroparesis-drug 2025-05-23T08:44:51+00:00 hourly 0.9 https://trial.medpath.com/news/51a7196298097968/fujitsu-and-thers-successfully-deploy-ai-to-accelerate-clinical-trial-recruitment-and-combat-drug-loss-in-japan 2025-05-23T08:12:53+00:00 hourly 0.9 https://trial.medpath.com/news/0117c1fdf4819d41/gene-editing-faces-uncertainty-as-crispr-companies-navigate-regulatory-challenges 2025-05-23T07:38:51+00:00 hourly 0.9 https://trial.medpath.com/news/052517c119213705/mythic-therapeutics-mytx-011-shows-promising-efficacy-in-phase-1-trial-for-advanced-nsclc 2025-05-23T05:43:40+00:00 hourly 0.9 https://trial.medpath.com/news/195d28410d0e46fe/gntbm-presents-promising-preclinical-data-for-novel-epigenetic-immune-activator-at-asco-2025 2025-05-23T04:44:48+00:00 hourly 0.9 https://trial.medpath.com/news/084dd03eff4def02/ruxolitinib-shows-promise-in-treating-car-t-cell-therapy-induced-parkinsonism-in-multiple-myeloma 2025-05-23T04:44:47+00:00 hourly 0.9 https://trial.medpath.com/news/f8551e4d40cb976b/federal-circuit-upholds-pfizer-s-victory-in-gene-therapy-patent-dispute-for-hemophilia-treatment 2025-05-23T04:43:59+00:00 hourly 0.9 https://trial.medpath.com/news/136bcd4c852def71/maha-commission-proposes-comprehensive-pediatric-drug-safety-research-initiative 2025-05-23T04:43:52+00:00 hourly 0.9 https://trial.medpath.com/news/2d6fda0f1b370871/e7386-shows-promising-results-in-advanced-endometrial-cancer-trial-with-30-response-rate 2025-05-23T04:43:50+00:00 hourly 0.9 https://trial.medpath.com/news/b7b7ee3b27772460/dual-targeting-radiopharmaceutical-shows-89-response-rate-in-advanced-cancer-trial 2025-05-23T04:16:43+00:00 hourly 0.9 https://trial.medpath.com/news/3631eda11df10863/servier-to-present-phase-3-data-on-idh-mutated-cancer-therapies-at-asco-2025 2025-05-23T04:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/db8803208ce68526/flatiron-health-to-present-14-real-world-oncology-data-studies-at-asco-2025 2025-05-23T02:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/799345f610fdc46e/major-pharmaceutical-companies-expand-u-s-manufacturing-operations-creating-thousands-of-new-jobs 2025-05-23T02:47:05+00:00 hourly 0.9 https://trial.medpath.com/news/0129016c958022aa/soligenix-advances-sgx943-as-novel-antibiotic-alternative-to-combat-drug-resistant-bacterial-infections 2025-05-23T02:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/fe12c9b9837cf99c/auxilium-biotechnologies-initiates-pivotal-trial-for-neurospan-bridge-nerve-regeneration-device 2025-05-23T01:47:09+00:00 hourly 0.9 https://trial.medpath.com/news/bfe6c640f14142d7/rigel-pharmaceuticals-unveils-promising-final-data-from-gavreto-and-rezlidhia-clinical-trials-at-asco-and-eha-2025 2025-05-23T01:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/752ad7e4cf4d7f51/exelixis-reports-promising-results-for-zanzalintinib-combination-in-advanced-kidney-cancer 2025-05-23T01:17:12+00:00 hourly 0.9 https://trial.medpath.com/news/0f1a0aa61b039f80/miradx-and-ucla-to-present-groundbreaking-research-on-microrna-based-predictive-biomarkers-at-asco-2025 2025-05-23T00:46:48+00:00 hourly 0.9 https://trial.medpath.com/news/8d200a11edcd5bfc/zepzelca-tecentriq-combination-shows-survival-benefit-in-metastatic-small-cell-lung-cancer 2025-05-23T00:44:34+00:00 hourly 0.9 https://trial.medpath.com/news/01f83b6e2728cee5/boehringer-ingelheim-reports-promising-results-for-sirp-inhibitors-in-cancer-immunotherapy-trials 2025-05-23T00:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/07a00566253b533e/volastra-s-novel-kif18a-inhibitor-shows-promising-results-in-ovarian-cancer-patients 2025-05-23T00:16:39+00:00 hourly 0.9 https://trial.medpath.com/news/236c5ebffdb121ca/linvoseltamab-combination-therapy-shows-90-response-rate-in-relapsed-refractory-multiple-myeloma 2025-05-23T00:16:26+00:00 hourly 0.9 https://trial.medpath.com/news/0f07b8731dded586/amtagvi-shows-unprecedented-20-five-year-survival-rate-in-advanced-melanoma-patients 2025-05-23T00:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/83e0845ce0ca9798/merus-reports-promising-survival-data-for-petosemtamab-keytruda-combination-in-metastatic-head-and-neck-cancer 2025-05-23T00:15:19+00:00 hourly 0.9 https://trial.medpath.com/news/2308b7248611f1c2/rwjbarnabas-health-and-rutgers-cancer-institute-to-present-45-groundbreaking-studies-at-asco-2025 2025-05-23T00:15:14+00:00 hourly 0.9 https://trial.medpath.com/news/d0dd598bbb9c2d21/new-onset-diabetes-emerges-as-early-warning-signal-for-pancreatic-cancer-detection 2025-05-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9fb5ff98625252aa/microneedle-technology-emerges-as-game-changer-for-targeted-drug-delivery-and-vaccine-administration 2025-05-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0324ae64c89b2edb/city-of-hope-to-present-groundbreaking-cancer-advances-at-2025-asco-annual-meeting 2025-05-22T23:45:10+00:00 hourly 0.9 https://trial.medpath.com/news/10fbecca9d29d83f/cizzle-bio-s-ciz1b-blood-test-could-save-medicare-518-million-annually-in-lung-cancer-screening 2025-05-22T23:45:08+00:00 hourly 0.9 https://trial.medpath.com/news/6f2c6f31ddf285ba/biomed-x-and-boehringer-ingelheim-complete-groundbreaking-schizophrenia-research-project 2025-05-22T22:44:54+00:00 hourly 0.9 https://trial.medpath.com/news/b475fcb8dd270b20/shilpa-biologicals-expands-adc-capabilities-with-new-bioconjugation-facility-in-india 2025-05-22T22:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/91a40cc691d5d50c/satellos-reports-promising-efficacy-signals-for-novel-dmd-treatment-in-adult-patients 2025-05-22T22:15:50+00:00 hourly 0.9 https://trial.medpath.com/news/debafe0585c79d54/fda-approves-gsk-s-nucala-for-copd-treatment-expanding-options-for-smoker-s-lung 2025-05-22T22:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/5a36412bd4edfcf5/roche-and-ascidian-forge-1-8-billion-partnership-for-neurological-disease-drug-development 2025-05-22T21:45:24+00:00 hourly 0.9 https://trial.medpath.com/news/9c63c5d5f2a2194f/eli-lilly-enters-1-3-billion-rna-therapy-partnership-to-expand-genetic-hearing-loss-pipeline 2025-05-22T21:45:14+00:00 hourly 0.9 https://trial.medpath.com/news/c8c223d9bf20ff78/daiichi-sankyo-presents-breakthrough-enhertu-data-at-asco-2025-with-two-late-breaking-phase-3-trials 2025-05-22T21:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/b4d84c8adbaef743/lupkynis-based-triple-therapy-shows-superior-proteinuria-reduction-in-lupus-nephritis-patients 2025-05-22T20:38:55+00:00 hourly 0.9 https://trial.medpath.com/news/41099904de65ce04/eu-establishes-emergency-compulsory-licensing-framework-for-pharmaceutical-patents-with-key-limitations 2025-05-22T20:38:42+00:00 hourly 0.9 https://trial.medpath.com/news/e94debb560370ea3/setu-secures-eur159589-grant-for-novel-gene-therapy-research-in-fatal-childhood-canavan-disease 2025-05-22T20:38:23+00:00 hourly 0.9 https://trial.medpath.com/news/c070d4ef2600c1fe/nih-scientists-develop-novel-surgical-technique-to-enhance-cell-therapy-for-dry-age-related-macular-degeneration 2025-05-22T20:38:15+00:00 hourly 0.9 https://trial.medpath.com/news/bf3d86a212757c32/instil-bio-and-immuneonco-advance-pd-l-1xvegf-bispecific-antibody-clinical-development-strategy 2025-05-22T20:37:59+00:00 hourly 0.9 https://trial.medpath.com/news/830b963520cbebe8/alteogen-s-aflibercept-biosimilar-eyluxvi-receives-positive-opinion-from-european-medicines-agency 2025-05-22T20:19:10+00:00 hourly 0.9 https://trial.medpath.com/news/5f37a2c10ab217ae/instil-bio-s-pd-l1xvegf-bispecific-antibody-shows-promise-in-nsclc-driving-48-stock-surge 2025-05-22T20:18:42+00:00 hourly 0.9 https://trial.medpath.com/news/f69a342d4746f7c9/trump-s-tax-bill-passes-house-with-pharma-reforms-ira-pill-penalty-remains-unchanged 2025-05-22T20:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/212e6a4fcd64fa8f/dupont-launches-amberchrom-tq1-chromatography-resin-to-advance-oligonucleotide-and-peptide-purification 2025-05-22T20:16:14+00:00 hourly 0.9 https://trial.medpath.com/news/2d239752f08954cc/pacbio-partners-with-haorui-gene-to-expand-long-read-sequencing-access-across-china 2025-05-22T19:44:36+00:00 hourly 0.9 https://trial.medpath.com/news/05017c3d22df12d4/vitamin-d-supplementation-shown-to-slow-biological-aging-in-landmark-vital-trial 2025-05-22T19:44:27+00:00 hourly 0.9 https://trial.medpath.com/news/e1edec27d2599215/biogen-sues-neurimmune-over-rights-to-novel-alzheimer-s-bispecific-antibody-technology 2025-05-22T19:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/0ea498dd9162a940/fore-biotherapeutics-secures-38-million-in-series-d-2-financing-to-advance-plixorafenib-clinical-trials 2025-05-22T17:38:02+00:00 hourly 0.9 https://trial.medpath.com/news/05f77dd2c80303fb/u-s-drug-prices-double-as-pharmaceutical-industry-shifts-focus-to-rare-diseases 2025-05-22T17:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/9d802456694854c5/bayer-launches-centafore-new-imaging-core-lab-to-enhance-clinical-trial-imaging-and-samd-development 2025-05-22T17:15:32+00:00 hourly 0.9 https://trial.medpath.com/news/bdcb0d492ef151bc/rubedo-life-sciences-initiates-first-ever-gpx4-modulator-clinical-trial-for-psoriasis-and-skin-aging 2025-05-22T16:40:46+00:00 hourly 0.9 https://trial.medpath.com/news/e002f6f2a1fe62ab/meril-s-myval-thv-series-demonstrates-non-inferiority-in-landmark-head-to-head-tavi-trial 2025-05-22T16:40:04+00:00 hourly 0.9 https://trial.medpath.com/news/909ea970919d03c8/cureduchenne-ventures-invests-1m-in-entos-pharmaceuticals-for-novel-duchenne-muscular-dystrophy-gene-therapy 2025-05-22T16:38:55+00:00 hourly 0.9 https://trial.medpath.com/news/a20cb31339261d27/novel-nasal-spray-gene-therapy-shows-promise-for-treating-lung-diseases 2025-05-22T16:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/a4ebf4108ee05001/peptide-drug-conjugates-emerge-as-next-generation-cancer-therapeutics-with-over-30-candidates-in-clinical-development 2025-05-22T16:38:13+00:00 hourly 0.9 https://trial.medpath.com/news/aee7352dcc8965b2/kfshrc-and-cellenkos-partner-to-advance-treg-cell-therapies-for-rare-diseases-in-landmark-saudi-us-collaboration 2025-05-22T16:38:07+00:00 hourly 0.9 https://trial.medpath.com/news/80873696dbc21171/neuropeutics-inc-wins-abbvie-biotech-innovators-award-for-novel-neurodegenerative-disease-therapies 2025-05-22T16:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/99d238947e196f1e/large-norwegian-study-finds-no-increased-risk-of-autism-or-adhd-in-children-exposed-to-triptans-during-pregnancy 2025-05-22T16:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/a912e12d862a0822/zyus-life-sciences-prepares-to-launch-phase-2a-trial-of-novel-cannabinoid-based-pain-therapy-for-cancer-patients 2025-05-22T16:25:26+00:00 hourly 0.9 https://trial.medpath.com/news/a4e03b20842b065e/uk-high-court-rules-amgen-and-samsung-bioepis-soliris-biosimilars-do-not-infringe-alexion-patent 2025-05-22T16:25:24+00:00 hourly 0.9 https://trial.medpath.com/news/6a9c2c1c9f23446b/merck-kgaa-acquires-aptoll-from-aptatargets-for-acute-ischemic-stroke-treatment 2025-05-22T16:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/ca7fb3ca061495cd/repronovo-secures-65m-series-a-to-revive-failed-fertility-drug-nolasiban 2025-05-22T16:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/e6088306b1d91d8d/syantra-expands-ip-portfolio-with-novel-tumor-education-approach-for-cancer-detection-and-treatment 2025-05-22T16:23:53+00:00 hourly 0.9 https://trial.medpath.com/news/d767d812202c3611/aptahem-advances-apta-1-to-phase-ii-as-european-pharma-company-expresses-strong-partnership-interest 2025-05-22T16:23:15+00:00 hourly 0.9 https://trial.medpath.com/news/978d7c5950d9004b/fda-approves-rejoyn-first-prescription-digital-therapeutic-for-major-depressive-disorder 2025-05-22T16:21:47+00:00 hourly 0.9 https://trial.medpath.com/news/fdf02083eebf7ffe/astrazeneca-s-gremubamab-shows-promise-in-reducing-pseudomonas-infection-in-bronchiectasis-patients 2025-05-22T16:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/6f2b9eae7a5861dd/lenvatinib-plus-pd-1-l1-inhibitors-shows-superior-efficacy-over-bevacizumab-combinations-in-unresectable-hepatocellular-carcinoma 2025-05-22T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/770dc81db7004681/neogenomics-launches-c-met-companion-diagnostic-for-advanced-non-small-cell-lung-cancer-treatment 2025-05-22T15:43:18+00:00 hourly 0.9 https://trial.medpath.com/news/520a6b8f8d43f98f/citrin-foundation-and-university-children-s-hospital-zurich-launch-pioneering-center-for-urea-cycle-disorders-research 2025-05-22T14:45:23+00:00 hourly 0.9 https://trial.medpath.com/news/88463bd89dea3a35/augustine-therapeutics-appoints-rie-schultz-hansen-as-cso-establishes-copenhagen-subsidiary-to-advance-hdac6-inhibitor-pipeline 2025-05-22T14:44:42+00:00 hourly 0.9 https://trial.medpath.com/news/f809f6f162978856/astrazeneca-and-aptar-digital-health-partner-to-develop-ai-algorithms-for-early-detection-of-chronic-kidney-disease 2025-05-22T14:43:44+00:00 hourly 0.9 https://trial.medpath.com/news/ee0586dbe5108ae1/fda-streamlines-canadian-drug-importation-process-to-lower-us-prescription-costs 2025-05-22T13:46:01+00:00 hourly 0.9 https://trial.medpath.com/news/03feb9f55e71d118/duke-university-develops-sbi-810-novel-non-opioid-painkiller-targeting-specific-brain-receptors 2025-05-22T13:43:30+00:00 hourly 0.9 https://trial.medpath.com/news/bae03b1f3991b5bc/phase-scientific-secures-34-million-to-advance-urine-based-cancer-diagnostics 2025-05-22T12:48:02+00:00 hourly 0.9 https://trial.medpath.com/news/065fc85b3830e158/novo-nordisk-ceo-steps-down-after-eight-years-as-company-faces-market-pressures 2025-05-22T12:47:19+00:00 hourly 0.9 https://trial.medpath.com/news/4ea6a892336be31f/fda-clears-ascletis-ind-for-asc50-a-novel-oral-il-17-inhibitor-for-psoriasis-treatment 2025-05-22T12:47:16+00:00 hourly 0.9 https://trial.medpath.com/news/5a20f97c44dc6c5d/vicore-pharma-s-buloxibutid-shows-superior-anti-fibrotic-activity-for-ipf-treatment-in-new-data 2025-05-22T12:46:35+00:00 hourly 0.9 https://trial.medpath.com/news/2b4febcef084cc4e/fda-convenes-expert-panel-to-evaluate-talc-safety-in-food-and-drugs 2025-05-22T12:46:25+00:00 hourly 0.9 https://trial.medpath.com/news/6dc0cc889ae4ed13/comac-medical-group-acquires-ilife-consulting-to-strengthen-oncology-and-early-phase-trial-capabilities 2025-05-22T12:45:43+00:00 hourly 0.9 https://trial.medpath.com/news/939319fca12b2130/vyloy-leads-claudin-18-2-targeted-therapy-revolution-with-60-drug-candidates-in-pipeline 2025-05-22T12:45:34+00:00 hourly 0.9 https://trial.medpath.com/news/fab51d02466a4bce/uk-biopharma-venture-funding-hits-1-1-billion-in-q1-2025-signaling-strong-industry-growth 2025-05-22T12:44:33+00:00 hourly 0.9 https://trial.medpath.com/news/10220fcc88dfda68/samsung-bioepis-to-become-wholly-owned-subsidiary-of-samsung-biologics-in-strategic-restructuring 2025-05-22T12:44:28+00:00 hourly 0.9 https://trial.medpath.com/news/9096c26f50542762/replimune-s-rp1-melanoma-therapy-nears-fda-decision-with-july-pdufa-date-as-commercial-infrastructure-readies-for-launch 2025-05-22T12:44:24+00:00 hourly 0.9 https://trial.medpath.com/news/f3ac4e601c83cec2/malaysia-extends-biocon-biologics-insulin-supply-contract-for-six-additional-months 2025-05-22T12:44:17+00:00 hourly 0.9 https://trial.medpath.com/news/a9e0205f330a5827/route-92-medical-s-hipoint-88-reperfusion-system-achieves-record-first-pass-effect-in-stroke-thrombectomy-trial 2025-05-22T12:44:01+00:00 hourly 0.9 https://trial.medpath.com/news/1d75843dfafb513f/new-sickle-cell-disease-therapies-expand-options-but-access-barriers-remain 2025-05-22T12:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/c68687bb8c0ed37e/new-cryogenic-mass-spectrometry-method-reveals-lipid-nanoparticle-structure-advancing-rna-therapeutics 2025-05-22T12:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/860b6e0c1945de3e/merck-kgaa-advances-lupus-drug-to-phase-iii-despite-mixed-clinical-results 2025-05-22T12:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/85f1b5d4c85e39d2/nanoparticle-based-drug-delivery-systems-show-promise-for-enhancing-cancer-immunotherapy-in-solid-tumors 2025-05-22T11:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/f95fca5fbfc28078/ucla-study-reveals-ssris-may-enhance-immune-response-against-cancer 2025-05-22T09:36:09+00:00 hourly 0.9 https://trial.medpath.com/news/8fddce3660f0bbb3/elicera-s-itank-armed-car-t-cell-therapy-shows-complete-response-in-lymphoma-patients 2025-05-22T08:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/20ad74a8dc62f77b/dual-mtorc1-2-inhibitor-bi-860585-shows-promise-in-phase-i-breast-cancer-trial 2025-05-22T08:37:49+00:00 hourly 0.9 https://trial.medpath.com/news/3e9011dba2ed4e89/fda-grants-rare-pediatric-disease-designation-to-relief-therapeutics-eb-treatment-rlf-td011 2025-05-22T08:36:09+00:00 hourly 0.9 https://trial.medpath.com/news/a5b60fb2ee7b0af9/medipharm-labs-advances-4-5-million-asset-sale-to-strengthen-financial-position-for-international-expansion 2025-05-22T08:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/99f5114c69160891/intalight-s-dream-oct-platform-receives-ce-mark-approval-for-european-market 2025-05-22T08:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/1595362463497631/viz-ai-partners-with-sanofi-and-regeneron-to-deploy-ai-powered-copd-management-solution 2025-05-22T05:44:25+00:00 hourly 0.9 https://trial.medpath.com/news/9412f92e93253e1c/strategic-patent-extensions-and-505-b-2-applications-key-pathways-for-post-anda-market-exclusivity 2025-05-22T04:45:06+00:00 hourly 0.9 https://trial.medpath.com/news/4ec057cb6e23ab62/surgeons-complete-world-s-first-human-bladder-transplant-in-groundbreaking-procedure 2025-05-22T04:44:26+00:00 hourly 0.9 https://trial.medpath.com/news/5a66f68f4a80c0e1/nus-researchers-develop-next-a-revolutionary-gene-delivery-platform-for-cancer-immunotherapy 2025-05-22T04:44:25+00:00 hourly 0.9 https://trial.medpath.com/news/9b57578e799a3ace/annji-pharmaceutical-reports-promising-phase-1-2a-results-for-aj201-in-sbma-a-rare-neuromuscular-disease 2025-05-22T04:44:21+00:00 hourly 0.9 https://trial.medpath.com/news/efb5d4556d48da14/samsung-biologics-to-spin-off-biosimilar-business-to-focus-on-core-cdmo-services 2025-05-22T04:43:46+00:00 hourly 0.9 https://trial.medpath.com/news/2beb7e2de3be46e0/international-r-d-partnerships-drive-innovation-and-accessibility-in-generic-drug-development 2025-05-22T04:43:43+00:00 hourly 0.9 https://trial.medpath.com/news/8389ce25ffaef5d4/mayo-clinic-researchers-discover-drug-treatment-to-triple-donor-heart-preservation-time 2025-05-22T03:43:29+00:00 hourly 0.9 https://trial.medpath.com/news/810b2d7ed41ceab4/pharmacists-take-central-role-in-managing-novel-cancer-therapies-as-car-t-and-bispecific-antibodies-transform-treatment-landscape 2025-05-22T02:41:05+00:00 hourly 0.9 https://trial.medpath.com/news/34b04c219ab80e8b/fda-clears-avenzo-therapeutics-ind-for-avzo-023-a-novel-cdk4-selective-inhibitor-for-advanced-breast-cancer 2025-05-22T00:47:22+00:00 hourly 0.9 https://trial.medpath.com/news/97e781a662cf6d36/sanofi-to-acquire-vigil-neuroscience-for-up-to-600-million-expanding-alzheimer-s-disease-pipeline 2025-05-22T00:47:20+00:00 hourly 0.9 https://trial.medpath.com/news/8a7eef2ff493ffe1/india-s-cdsco-approves-two-cancer-drugs-with-phase-iv-trial-requirements 2025-05-22T00:19:18+00:00 hourly 0.9 https://trial.medpath.com/news/8ea3c53f9b870f08/cel-sci-secures-5-million-in-public-offering-to-advance-multikine-immunotherapy-for-head-and-neck-cancer 2025-05-22T00:15:16+00:00 hourly 0.9 https://trial.medpath.com/news/c7d56c6df1a0acd6/merck-leadership-to-present-at-major-healthcare-investment-conferences-in-2025 2025-05-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0f88d7112d1358f3/extracellular-vesicles-emerge-as-dual-players-in-cancer-immunotherapy-resistance-and-treatment-innovation 2025-05-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/53ee700755c12f27/new-ai-blood-test-artemis-delfi-shows-promise-for-monitoring-pancreatic-cancer-treatment-response 2025-05-21T23:48:42+00:00 hourly 0.9 https://trial.medpath.com/news/d06b14f95cd2ca6e/revolutionary-blood-test-achieves-99-accuracy-in-detecting-hpv-associated-head-and-neck-cancers 2025-05-21T23:47:25+00:00 hourly 0.9 https://trial.medpath.com/news/5a7cc07430c6ff3b/childhood-cancer-survivors-face-five-fold-higher-risk-of-kidney-disease-and-hypertension 2025-05-21T23:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/46726bf2f2430806/bausch-lomb-s-lumify-preservative-free-eye-drops-demonstrate-non-inferiority-in-phase-3-trial 2025-05-21T22:47:11+00:00 hourly 0.9 https://trial.medpath.com/news/690bff853bfb1f50/onward-medical-advances-brain-computer-interface-technology-with-fifth-successful-implant-for-spinal-cord-injury-patients 2025-05-21T22:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/11823f15b819a1ee/repronovo-secures-65-million-series-a-funding-to-advance-novel-reproductive-medicine-therapies 2025-05-21T20:47:08+00:00 hourly 0.9 https://trial.medpath.com/news/a31edb933565aa51/california-s-ab-824-pharmaceutical-patent-settlement-law-faces-permanent-injunction-limiting-enforcement 2025-05-21T20:46:14+00:00 hourly 0.9 https://trial.medpath.com/news/8e6903dbd47f5986/rainbow-children-s-hospital-completes-eighth-zolgensma-gene-therapy-for-spinal-muscular-atrophy-in-india 2025-05-21T20:45:19+00:00 hourly 0.9 https://trial.medpath.com/news/9b57a1fb99b1a254/south-rampart-pharma-secures-new-investment-for-novel-non-opioid-pain-treatment 2025-05-21T20:45:16+00:00 hourly 0.9 https://trial.medpath.com/news/23444a782a566344/ftc-issues-new-warnings-to-teva-and-novartis-over-improper-orange-book-patent-listings 2025-05-21T20:44:05+00:00 hourly 0.9 https://trial.medpath.com/news/3684cc463f231c84/study-identifies-why-venetoclax-based-aml-treatment-fails-in-certain-patients 2025-05-21T20:43:49+00:00 hourly 0.9 https://trial.medpath.com/news/5f9429087135c1ab/montara-therapeutics-receives-3-3m-grant-from-michael-j-fox-foundation-to-develop-brain-selective-lrrk2-inhibitor-for-parkinson-s 2025-05-21T20:43:46+00:00 hourly 0.9 https://trial.medpath.com/news/ba98d2b4eaeef592/fda-approves-clinical-trial-of-atia-vision-s-innovative-omnivu-lens-system-for-cataract-patients 2025-05-21T20:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/aa179ff26fd72521/nih-funded-teams-develop-precision-gene-delivery-systems-for-neural-cells 2025-05-21T18:13:58+00:00 hourly 0.9 https://trial.medpath.com/news/9899ca71c95d30b5/senores-pharmaceuticals-acquires-anda-for-enalapril-maleate-tablets-from-wockhardt 2025-05-21T16:53:37+00:00 hourly 0.9 https://trial.medpath.com/news/95cbb89941cdb5b0/resistance-to-til-therapy-in-lung-cancer-mediated-by-clonal-t-cell-loss-and-neoantigen-escape 2025-05-21T16:52:19+00:00 hourly 0.9 https://trial.medpath.com/news/c8814e48b34c1efe/fda-supports-novel-endpoints-for-abli-therapeutics-risvodetinib-phase-3-trial-in-parkinson-s-disease 2025-05-21T16:52:11+00:00 hourly 0.9 https://trial.medpath.com/news/57a917a081704215/ose-immunotherapeutics-leads-eur1-3-million-consortium-to-advance-mrna-therapeutics-using-lipid-nanoparticle-technology 2025-05-21T16:52:02+00:00 hourly 0.9 https://trial.medpath.com/news/fc836cc70ff15571/fda-expands-warning-for-mrna-covid-19-vaccines-due-to-heart-side-effect-risk-in-young-males 2025-05-21T16:51:58+00:00 hourly 0.9 https://trial.medpath.com/news/ff0601ffecdfc409/waters-acquires-halo-labs-to-enhance-biologic-therapy-analysis-capabilities 2025-05-21T16:51:04+00:00 hourly 0.9 https://trial.medpath.com/news/389be9d9a52a9799/telomir-pharmaceuticals-secures-3-million-investment-to-advance-novel-age-reversal-drug-for-rare-diseases 2025-05-21T16:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/2259fffdef948659/breakthrough-clinical-trial-shows-vagus-nerve-stimulation-significantly-improves-spinal-cord-injury-recovery 2025-05-21T16:50:08+00:00 hourly 0.9 https://trial.medpath.com/news/0ee8953e4d9c6219/alzheimer-s-drug-pipeline-shows-promising-diversity-as-88-trials-recruit-patients-in-2025 2025-05-21T16:50:06+00:00 hourly 0.9 https://trial.medpath.com/news/9ea6da887961db88/reshape-lifesciences-announces-merger-with-vyome-and-asset-sale-to-biorad-amid-q1-2025-financial-results 2025-05-21T16:49:19+00:00 hourly 0.9 https://trial.medpath.com/news/908f4ae8f745c7a9/basil-systems-secures-11-5m-to-revolutionize-life-sciences-decision-making-with-ai 2025-05-21T16:49:11+00:00 hourly 0.9 https://trial.medpath.com/news/4a6fa61859e1a7c7/fresenius-kabi-launches-tyenne-r-canada-s-first-tocilizumab-biosimilar-for-autoimmune-conditions 2025-05-21T16:48:27+00:00 hourly 0.9 https://trial.medpath.com/news/4d947eb21ab23c8f/meta-analysis-confirms-efficacy-of-traditional-chinese-medicine-si-shen-wan-for-treating-ibs-d 2025-05-21T16:48:26+00:00 hourly 0.9 https://trial.medpath.com/news/aa080d835494001d/mazindol-er-shows-promising-dual-action-against-fentanyl-addiction-in-preclinical-studies 2025-05-21T16:48:12+00:00 hourly 0.9 https://trial.medpath.com/news/066ed6f0bba62531/protagenic-therapeutics-secures-3-1-million-to-advance-cns-drug-pipeline-following-phytanix-bio-merger 2025-05-21T16:47:17+00:00 hourly 0.9 https://trial.medpath.com/news/61af057904c64c18/biodlink-secures-brazil-gmp-certification-expanding-global-reach-for-bevacizumab-biosimilar 2025-05-21T16:46:46+00:00 hourly 0.9 https://trial.medpath.com/news/a051e0d41441facd/synfini-and-multispan-partner-to-accelerate-gpcr-drug-discovery-using-ai-and-automation 2025-05-21T16:46:40+00:00 hourly 0.9 https://trial.medpath.com/news/807749e40caa66c7/uni-bio-science-group-s-diquafosol-sodium-eye-drops-receives-nmpa-approval-for-dry-eye-syndrome-treatment-in-china 2025-05-21T16:46:38+00:00 hourly 0.9 https://trial.medpath.com/news/5244127d2ed6f70e/ai-tools-show-promise-in-improving-her2-breast-cancer-classification-and-treatment-eligibility 2025-05-21T16:46:29+00:00 hourly 0.9 https://trial.medpath.com/news/76c24fee8e93800d/biosergen-s-bsg005-shows-promise-against-resistant-fungal-infections-in-clinical-trial 2025-05-21T16:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/f3fa884804fcd180/tecentriq-and-avastin-combined-with-tace-shows-significant-benefit-in-unresectable-liver-cancer-trial 2025-05-21T16:12:33+00:00 hourly 0.9 https://trial.medpath.com/news/dacb64123961caa1/bioxytran-s-antiviral-phm23-selected-for-university-of-georgia-s-100m-bird-flu-challenge-submission 2025-05-21T16:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/cde6b353e35c0166/cipla-launches-zemdri-plazomicin-in-india-to-combat-antimicrobial-resistance 2025-05-21T16:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/408755680efa3c9a/new-global-report-reveals-comprehensive-landscape-of-chemotherapy-induced-diarrhea-clinical-trials 2025-05-21T16:10:35+00:00 hourly 0.9 https://trial.medpath.com/news/0ba18d9e1a94a1ec/worldwide-clinical-trials-joins-wcg-s-avoca-quality-consortium-to-enhance-clinical-trial-standards 2025-05-21T16:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/b6d7092643b6d2b8/patient-derived-organoids-and-crispr-technology-transform-cancer-research-and-precision-medicine 2025-05-21T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2b3674b3d2094164/first-patient-dosed-in-phase-2-oasis-trial-of-tnx-102-sl-for-acute-stress-reaction-following-trauma 2025-05-21T15:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/f9559645bab872aa/upstream-bio-appoints-stacy-price-as-chief-technology-officer-to-advance-verekitug-development 2025-05-21T15:13:59+00:00 hourly 0.9 https://trial.medpath.com/news/3286a90d5649f917/mallia-therapeutics-advances-novel-scd83-protein-treatment-for-hair-loss 2025-05-21T14:44:07+00:00 hourly 0.9 https://trial.medpath.com/news/a9af8e6fd7f6a134/pace-life-sciences-passes-fda-pre-approval-inspection-strengthening-contract-manufacturing-capabilities 2025-05-21T14:15:34+00:00 hourly 0.9 https://trial.medpath.com/news/32707539f90f938f/medtronic-plans-to-separate-diabetes-business-into-standalone-company 2025-05-21T13:44:18+00:00 hourly 0.9 https://trial.medpath.com/news/fe4210a6375bd137/faron-pharmaceuticals-appoints-ralph-hughes-as-chief-business-officer-to-advance-immunotherapy-pipeline 2025-05-21T13:44:11+00:00 hourly 0.9 https://trial.medpath.com/news/fc6478921efd1119/clearflow-s-pleuraflow-system-reduces-cardiac-surgery-complications-by-41-in-large-clinical-trial 2025-05-21T13:43:56+00:00 hourly 0.9 https://trial.medpath.com/news/f9bbd288d7641a09/triveni-bio-initiates-first-in-human-trial-of-triv-509-for-atopic-dermatitis-targeting-novel-kallikrein-pathway 2025-05-21T13:16:34+00:00 hourly 0.9 https://trial.medpath.com/news/faee4dba337e2a49/me-therapeutics-secures-140000-in-funding-to-advance-novel-mrna-cancer-therapies 2025-05-21T12:46:36+00:00 hourly 0.9 https://trial.medpath.com/news/446732ac1070b5ae/moderna-withdraws-fda-application-for-flu-covid-combo-vaccine-plans-resubmission-later-this-year 2025-05-21T12:44:52+00:00 hourly 0.9 https://trial.medpath.com/news/d8553bff45f03d89/zura-bio-launches-phase-ii-tibushield-trial-for-novel-dual-inhibitor-in-hidradenitis-suppurativa 2025-05-21T12:43:54+00:00 hourly 0.9 https://trial.medpath.com/news/eb2645f5e2a50212/fda-grants-ind-clearance-for-immunoglobulin-eye-drops-to-treat-dry-eye-disease 2025-05-21T12:43:52+00:00 hourly 0.9 https://trial.medpath.com/news/4a2a1848ce101c3d/bharat-biotech-s-oral-cholera-vaccine-hillchol-successfully-completes-phase-iii-trials 2025-05-21T12:43:20+00:00 hourly 0.9 https://trial.medpath.com/news/52de96b4f1239754/dementia-discovery-fund-secures-269m-in-second-fund-to-accelerate-novel-therapeutics-development 2025-05-21T12:43:19+00:00 hourly 0.9 https://trial.medpath.com/news/158ef434d76d7088/obesity-drug-pipeline-surges-with-100-therapies-from-80-companies-in-2025 2025-05-21T12:43:15+00:00 hourly 0.9 https://trial.medpath.com/news/ae71604fe7279654/juvenescence-secures-76m-in-series-b-1-funding-led-by-abu-dhabi-s-m42-for-age-related-disease-therapeutics 2025-05-21T12:42:42+00:00 hourly 0.9 https://trial.medpath.com/news/8dec81f7cd1d9d40/delhi-high-court-overturns-patent-rejection-for-taiho-pharmaceutical-s-anticancer-compound 2025-05-21T12:42:40+00:00 hourly 0.9 https://trial.medpath.com/news/7f345429b186d454/astrazeneca-showcases-groundbreaking-cancer-research-at-asco-2025-with-two-plenary-presentations 2025-05-21T12:42:33+00:00 hourly 0.9 https://trial.medpath.com/news/12ff521504a5e886/msd-expands-opevesostat-clinical-program-to-include-breast-endometrial-and-ovarian-cancers 2025-05-21T12:42:29+00:00 hourly 0.9 https://trial.medpath.com/news/c3e7be1ede0fafa0/applied-stemcell-launches-hypoimmunogenic-hipsc-products-to-advance-allogeneic-cell-therapy-development 2025-05-21T12:42:23+00:00 hourly 0.9 https://trial.medpath.com/news/ee684ce003f704cd/closed-loop-medicine-appoints-kate-woolland-as-ceo-to-drive-precision-dosing-commercialization 2025-05-21T12:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/436720faabe29c84/mirai-bio-partners-with-thermo-fisher-scientific-to-accelerate-genetic-medicine-development 2025-05-21T09:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/f988fb2aa5042367/new-genetic-findings-challenge-traditional-understanding-of-coats-disease 2025-05-21T08:36:31+00:00 hourly 0.9 https://trial.medpath.com/news/cccc345f26c5d17a/sk-bioscience-wins-patent-dispute-against-pfizer-over-pneumococcal-vaccine-components 2025-05-21T05:14:54+00:00 hourly 0.9 https://trial.medpath.com/news/6d61c2e0d09fd219/tubulis-and-bristol-myers-squibb-advance-first-collaborative-tubutecan-adc-into-clinical-trials 2025-05-21T05:14:27+00:00 hourly 0.9 https://trial.medpath.com/news/c66690eb243bb66f/kaida-biopharma-partners-with-northway-biotech-to-advance-novel-prolactin-receptor-antagonist-kad101-for-platinum-resistant-ovarian-cancer 2025-05-21T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/48106c03934ce025/accropeutics-oral-tyk2-jak1-inhibitor-shows-strong-efficacy-in-phase-2-psoriasis-trial 2025-05-21T04:44:28+00:00 hourly 0.9 https://trial.medpath.com/news/75e289d06de3f0aa/codex-labs-shaant-clearskin-probiotic-receives-us-patent-for-acne-treatment 2025-05-21T04:43:53+00:00 hourly 0.9 https://trial.medpath.com/news/c03ed4066f38aaef/nhs-england-launches-world-first-gonorrhoea-vaccine-amid-record-infection-rates 2025-05-21T04:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/d58a942c9044c0f0/genomic-testing-emerges-as-critical-tool-in-brain-cancer-treatment-experts-emphasize 2025-05-21T03:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/90e7516e61228bc2/belimumab-shows-superior-efficacy-for-systemic-lupus-erythematosus-in-meta-analysis 2025-05-21T01:43:05+00:00 hourly 0.9 https://trial.medpath.com/news/be92137ca77b6f44/dupixent-demonstrates-superior-efficacy-over-xolair-in-first-head-to-head-respiratory-study 2025-05-21T01:43:03+00:00 hourly 0.9 https://trial.medpath.com/news/36746de9d30c04ec/moderna-opposes-arbutus-s-request-to-reconsider-patent-case-limitations-in-covid-19-vaccine-dispute 2025-05-21T00:39:51+00:00 hourly 0.9 https://trial.medpath.com/news/8c60d36ba43ef14b/abbvie-sues-hetero-labs-over-new-orilissa-patent-to-block-generic-endometriosis-drug 2025-05-21T00:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/227a52b1fb2d939b/novel-il-2-derivative-shows-complete-remission-in-advanced-skin-cancer-patient-after-one-year 2025-05-21T00:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/ff03a72839c276a6/bioage-labs-faces-investor-lawsuit-after-obesity-drug-trial-halted-on-safety-concerns 2025-05-21T00:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/9e273f74b4460c1f/bristol-myers-squibb-to-close-gene-therapy-manufacturing-facility-in-libertyville-illinois 2025-05-21T00:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/11eb1d15e46d8bd7/env-101-shows-promising-results-in-idiopathic-pulmonary-fibrosis-treatment-reducing-pulmonary-vessel-volume 2025-05-21T00:38:05+00:00 hourly 0.9 https://trial.medpath.com/news/00bdbdcd0fc2c5d9/network-meta-analysis-reveals-optimal-treatment-strategies-for-male-osteoporosis 2025-05-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/848aa43567274759/immediate-statin-therapy-reduces-cardiovascular-events-by-one-third-in-diabetes-patients 2025-05-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/33aefffdb46c74cb/fda-advisory-committee-votes-6-2-in-favor-of-daratumumab-for-high-risk-smoldering-multiple-myeloma 2025-05-20T23:19:28+00:00 hourly 0.9 https://trial.medpath.com/news/716c85902a284610/fda-advisory-committee-rejects-new-indications-for-genentech-s-columvi-and-pfizer-s-talzenna-combination 2025-05-20T23:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/6aba6876332bcc52/empower-cad-study-confirms-benefits-of-ivl-first-strategy-in-female-patients-with-calcified-coronary-lesions 2025-05-20T23:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/2df36749694538c1/vantai-and-blueprint-medicines-expand-collaboration-to-tackle-undruggable-targets-with-ai-powered-proximity-therapeutics 2025-05-20T22:49:40+00:00 hourly 0.9 https://trial.medpath.com/news/0c095f42ef1f7bc1/fresenius-kabi-launches-30-mg-30-ml-epinephrine-injection-for-emergency-care-and-septic-shock 2025-05-20T20:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/7562a6d515cd3384/stemrim-expands-global-patent-portfolio-for-redasemtide-cartilage-regeneration-therapy 2025-05-20T20:45:34+00:00 hourly 0.9 https://trial.medpath.com/news/50f978bcf618915b/poolbeg-pharma-secures-ps4-1-million-fundraising-to-advance-clinical-programs-in-oncology-and-obesity 2025-05-20T20:44:52+00:00 hourly 0.9 https://trial.medpath.com/news/cb8294a2efa42739/poolbeg-pharma-launches-ps4-million-equity-raise-to-advance-cancer-and-obesity-drug-candidates 2025-05-20T20:44:27+00:00 hourly 0.9 https://trial.medpath.com/news/6c715ebf5658e0cc/ccm-biosciences-to-present-breakthrough-4th-generation-egfr-inhibitors-for-nsclc-at-asco-2025 2025-05-20T20:43:48+00:00 hourly 0.9 https://trial.medpath.com/news/6bf18019342fa871/fda-issues-warning-about-severe-itching-after-discontinuing-common-allergy-medications 2025-05-20T20:23:32+00:00 hourly 0.9 https://trial.medpath.com/news/aff242e788b217ce/fda-advisory-committee-rejects-genentech-s-columvi-expansion-for-transplant-ineligible-dlbcl-patients 2025-05-20T20:22:36+00:00 hourly 0.9 https://trial.medpath.com/news/4fe6a1b3ff448b23/spider-venom-derived-peptide-shows-promise-in-post-prostatectomy-erectile-dysfunction-phase-ii-trial 2025-05-20T20:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/1cdcc7f23ccd76d7/brain-biotech-expands-european-footprint-with-full-acquisition-of-breatec-and-new-production-facility 2025-05-20T20:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/b98440f70a633537/spain-dramatically-reduces-timeframe-between-eu-drug-approval-and-reimbursement-decisions 2025-05-20T20:19:34+00:00 hourly 0.9 https://trial.medpath.com/news/bb62735e2cd499dd/glofitamab-gemox-shows-survival-benefit-in-phase-3-starglo-trial-for-r-r-dlbcl-but-fda-advisory-committee-questions-us-applicability 2025-05-20T20:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/0d83c0bd58f58cca/fda-approves-hyalex-orthopaedics-ide-supplement-for-pivotal-trial-of-freestyle-knee-implant 2025-05-20T20:17:41+00:00 hourly 0.9 https://trial.medpath.com/news/2896213f4eef42bf/tempus-and-verastem-partner-to-develop-companion-diagnostic-for-first-fda-approved-kras-mutant-lgsoc-treatment 2025-05-20T18:48:29+00:00 hourly 0.9 https://trial.medpath.com/news/8c9dd1dfdad805d8/cellprothera-partners-with-cellforcure-by-seqens-for-phase-3-manufacturing-of-heart-attack-cell-therapy 2025-05-20T18:45:50+00:00 hourly 0.9 https://trial.medpath.com/news/db24a14378d056c3/aging-impairs-car-t-cell-therapy-effectiveness-through-metabolic-decline-swiss-study-reveals 2025-05-20T18:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/3c09e0011f869804/tourmaline-bio-s-heart-disease-antibody-shows-promise-in-phase-2-but-shares-fall-amid-competition-concerns 2025-05-20T17:41:22+00:00 hourly 0.9 https://trial.medpath.com/news/c57655f2b6bf8b94/finnish-researchers-develop-gene-signature-test-to-predict-cancer-immunotherapy-response 2025-05-20T17:17:23+00:00 hourly 0.9 https://trial.medpath.com/news/3cc3a8f5320e82c5/usc-spine-center-joins-pivotal-clarity-trial-to-evaluate-nociscan-for-chronic-low-back-pain 2025-05-20T16:38:07+00:00 hourly 0.9 https://trial.medpath.com/news/f5dbeb8baede73b4/more-impact-ag-secures-us-patent-for-needle-free-speedinject-technology 2025-05-20T16:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/457866c736848061/lymphodepletion-enhances-mar-t-cell-therapy-efficacy-in-lymphoma-patients-marker-therapeutics-reports 2025-05-20T16:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/2ced2e8708ea9cbc/novel-baff-r-car-t-therapy-achieves-complete-response-in-heavily-pretreated-follicular-lymphoma-patient 2025-05-20T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/fc3c9bceb29998bd/fda-grants-orphan-drug-designation-to-poolbeg-pharma-s-polb-001-for-cancer-immunotherapy-induced-cytokine-release-syndrome 2025-05-20T16:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/dcf230559ebb6f9d/kalivir-advances-novel-oncolytic-immunotherapy-vet3-tgi-in-phase-1-1b-trial-for-advanced-solid-tumors 2025-05-20T16:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/3c529411107136b2/pharmaessentia-s-ropeginterferon-shows-promising-results-in-phase-3-trial-for-essential-thrombocythemia 2025-05-20T16:28:05+00:00 hourly 0.9 https://trial.medpath.com/news/a429d7e487e1ef2e/eisai-to-present-long-term-leap-002-data-and-novel-pipeline-advances-at-asco-2025 2025-05-20T16:27:06+00:00 hourly 0.9 https://trial.medpath.com/news/f9080076f2f3b6cc/actimed-therapeutics-launches-program-to-combat-muscle-loss-in-glp-1-treated-obesity-patients 2025-05-20T16:26:53+00:00 hourly 0.9 https://trial.medpath.com/news/e7796bf081fd687c/chop-researchers-develop-breakthrough-aav-vectors-for-brain-gene-therapy-at-lower-doses 2025-05-20T16:26:46+00:00 hourly 0.9 https://trial.medpath.com/news/0d3c648fb782c1a9/experimental-medication-shows-promise-in-treating-cocaine-addiction 2025-05-20T16:25:12+00:00 hourly 0.9 https://trial.medpath.com/news/963ae73988d8c41b/philikos-initiates-phase-1-2-trial-of-t-guard-for-diffuse-cutaneous-systemic-sclerosis 2025-05-20T16:25:03+00:00 hourly 0.9 https://trial.medpath.com/news/12802ef5e4c6bd4e/imec-unveils-revolutionary-miniaturized-ingestible-sensor-for-non-invasive-gut-health-monitoring 2025-05-20T16:24:56+00:00 hourly 0.9 https://trial.medpath.com/news/9521f9dad62d32a2/avicanna-sponsors-phase-ii-clinical-trial-to-evaluate-cannabis-extracts-for-osteoarthritis-pain 2025-05-20T16:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/a9567c3ecf00405f/biostate-ai-secures-12m-series-a-to-revolutionize-rna-sequencing-and-molecular-diagnostics 2025-05-20T16:22:03+00:00 hourly 0.9 https://trial.medpath.com/news/3f2cfce41a5c75eb/sanofi-and-regeneron-announce-aim4-trial-to-advance-personalized-asthma-treatment 2025-05-20T16:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/468f719e15604a8c/fda-grants-first-ever-clearance-for-pediatric-functional-dyspepsia-treatment-to-neuraxis-s-ib-stim 2025-05-20T16:18:53+00:00 hourly 0.9 https://trial.medpath.com/news/db0b582ec4405194/fda-greenlights-promontory-therapeutics-phase-3-trial-design-for-pt-112-in-metastatic-prostate-cancer 2025-05-20T16:18:16+00:00 hourly 0.9 https://trial.medpath.com/news/2e9525beffa1d9e4/fda-overhauls-covid-19-vaccine-approval-process-limiting-access-for-healthy-adults-and-children 2025-05-20T16:18:07+00:00 hourly 0.9 https://trial.medpath.com/news/b44253cd1fbe1672/maipl-therapeutics-and-endosure-form-alliance-to-accelerate-non-hormonal-endometriosis-treatment-development 2025-05-20T16:17:58+00:00 hourly 0.9 https://trial.medpath.com/news/ba598ba84d77a786/addf-invests-2-16-million-in-life-molecular-imaging-s-novel-pet-tracer-for-alzheimer-s-neuroinflammation 2025-05-20T16:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/ad7fc9241999de07/act-technology-shows-promising-results-in-enhancing-chemotherapy-for-colorectal-liver-metastases 2025-05-20T15:45:22+00:00 hourly 0.9 https://trial.medpath.com/news/d3890ff871a3aa89/novel-aav-capsid-variant-shows-superior-gene-delivery-to-brain-regions-affected-by-huntington-s-and-parkinson-s 2025-05-20T15:44:53+00:00 hourly 0.9 https://trial.medpath.com/news/2cb706c3632c986c/stryker-receives-fda-clearance-for-optablate-bvn-system-to-treat-chronic-lower-back-pain 2025-05-20T14:43:43+00:00 hourly 0.9 https://trial.medpath.com/news/e49bdb6a20a9ae2c/doron-therapeutics-advances-motys-for-knee-osteoarthritis-following-successful-fda-meeting 2025-05-20T12:44:58+00:00 hourly 0.9 https://trial.medpath.com/news/e6867dd0740ed514/minghui-pharmaceutical-initiates-phase-ii-trial-combining-pd-1xvegf-bispecific-with-trop-2-adc-for-advanced-nsclc 2025-05-20T12:44:35+00:00 hourly 0.9 https://trial.medpath.com/news/535c450eaa01bef9/safety-concerns-emerge-for-gold-based-cisplatin-mimics-in-cancer-treatment-development 2025-05-20T12:43:54+00:00 hourly 0.9 https://trial.medpath.com/news/f7a58011b62a708f/fda-upgrades-xinnate-s-tcp-25-trial-for-epidermolysis-bullosa-to-registrational-status 2025-05-20T12:43:39+00:00 hourly 0.9 https://trial.medpath.com/news/7e6542c3e08254cb/merck-and-imec-partner-to-develop-advanced-microphysiological-systems-platform-for-drug-discovery 2025-05-20T12:11:57+00:00 hourly 0.9 https://trial.medpath.com/news/3c63cc6bebfc906b/enibarcimab-shows-promising-results-in-biomarker-guided-septic-shock-treatment 2025-05-20T12:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/ddb86baa030affa7/pasithea-s-pas-004-outperforms-fda-approved-mek-inhibitor-in-preclinical-ibd-study 2025-05-20T12:10:44+00:00 hourly 0.9 https://trial.medpath.com/news/830f8d2ea187367a/real-world-data-confirms-trikafta-s-long-term-efficacy-as-gold-standard-in-cystic-fibrosis-treatment 2025-05-20T12:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/1ef17b3e7460832c/novel-drug-combination-shows-promise-for-b-cell-acute-lymphoblastic-leukemia-with-reduced-toxicity 2025-05-20T12:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/80643c305605d436/university-of-virginia-expands-manning-institute-of-biotechnology-with-66m-additional-contract 2025-05-20T12:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/42ddc19c85236731/bora-biologics-expands-san-diego-facility-with-2000l-bioreactor-capacity-to-meet-growing-cdmo-demand 2025-05-20T11:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/ee569ef1649634d3/nextcell-pharma-and-fujifilm-irvine-scientific-form-strategic-alliance-to-advance-msc-therapy-development 2025-05-20T10:12:02+00:00 hourly 0.9 https://trial.medpath.com/news/b520c5a62fa93085/regeneron-develops-novel-antibody-approaches-to-enable-aav-gene-therapy-redosing 2025-05-20T08:37:10+00:00 hourly 0.9 https://trial.medpath.com/news/358d93650b14a54f/veraxa-biotech-appoints-oncology-veteran-rick-austin-as-chief-scientific-officer-to-advance-novel-cancer-therapies 2025-05-20T08:36:12+00:00 hourly 0.9 https://trial.medpath.com/news/536af56307b83fbf/kancera-advances-cardiovascular-drug-pipeline-with-recardio-partnership-and-fda-engagement 2025-05-20T06:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/6feaff5c656e077a/new-global-review-reveals-comprehensive-landscape-of-interstitial-cystitis-clinical-trials-in-2025 2025-05-20T04:42:22+00:00 hourly 0.9 https://trial.medpath.com/news/9d7215d314310f36/pfizer-enters-6-billion-licensing-deal-with-china-s-3sbio-for-novel-cancer-drug 2025-05-20T04:42:13+00:00 hourly 0.9 https://trial.medpath.com/news/6bea9227ced03c31/gabapentin-shows-promise-in-extending-survival-for-glioblastoma-patients-mass-general-brigham-study-reveals 2025-05-20T04:42:12+00:00 hourly 0.9 https://trial.medpath.com/news/57c530ab52cb4b2b/nitrous-oxide-breakthrough-enables-safer-gene-therapy-delivery-to-brain 2025-05-20T04:42:08+00:00 hourly 0.9 https://trial.medpath.com/news/427fff4341cb2bb0/biomed-x-and-boehringer-ingelheim-launch-initiative-to-revolutionize-retinal-drug-delivery 2025-05-20T04:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/0cc582fc9d52b99c/fda-approves-teal-wand-first-at-home-hpv-self-collection-device-for-cervical-cancer-screening 2025-05-20T04:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/88a11a61198ebe10/reunion-neuroscience-completes-patient-dosing-in-phase-2-reconnect-trial-of-re104-for-postpartum-depression 2025-05-20T02:43:23+00:00 hourly 0.9 https://trial.medpath.com/news/0129678cd361cd99/fda-approves-first-blood-test-for-alzheimer-s-diagnosis-boosting-roche-and-bioarctic-shares 2025-05-20T02:42:52+00:00 hourly 0.9 https://trial.medpath.com/news/6d9106038f17135a/new-guidelines-and-therapies-reshape-acne-treatment-approach-in-2025 2025-05-20T02:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/5ab27c8f0a91d5d0/data-analysis-reveals-utilization-not-drug-prices-drives-340b-program-s-explosive-growth 2025-05-20T02:40:52+00:00 hourly 0.9 https://trial.medpath.com/news/775eae704059f69b/stryker-receives-fda-clearance-for-optablate-bvn-system-to-treat-chronic-low-back-pain 2025-05-20T02:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/2800570d88b27abc/fda-questions-pfizer-s-approach-to-expand-talzenna-s-indication-in-prostate-cancer 2025-05-20T02:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/3b5f7da2ebf1e692/regenxbio-secures-250-million-royalty-monetization-deal-to-advance-gene-therapy-pipeline 2025-05-20T02:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/16cbf9231526abfa/meta-analysis-reveals-safety-differences-between-lecanemab-and-donanemab-in-early-alzheimer-s-disease-treatment 2025-05-20T00:44:44+00:00 hourly 0.9 https://trial.medpath.com/news/f5847602b2c64806/virtual-trial-shows-combination-rescue-inhaler-reduces-severe-asthma-attacks-by-nearly-50 2025-05-20T00:43:57+00:00 hourly 0.9 https://trial.medpath.com/news/201ef1cb7a16a7dc/fda-advisory-committee-rejects-pfizer-s-talzenna-expansion-for-broader-prostate-cancer-population 2025-05-20T00:43:52+00:00 hourly 0.9 https://trial.medpath.com/news/ae7fc1acdb1d250d/be-biopharma-initiates-first-in-human-trial-of-crispr-based-gene-therapy-for-haemophilia-b 2025-05-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1f28a143912fb5bc/casi-pharmaceuticals-to-host-conference-call-on-may-21-to-provide-business-and-clinical-updates 2025-05-19T23:17:06+00:00 hourly 0.9 https://trial.medpath.com/news/0c334043b5bc1e7c/nextcell-pharma-strengthens-commercial-strategy-with-appointment-of-msc-therapy-expert-dr-eric-strati 2025-05-19T22:46:26+00:00 hourly 0.9 https://trial.medpath.com/news/98991479cc1ce02f/lexicon-s-sonata-hcm-phase-3-trial-design-unveiled-at-european-cardiology-congress 2025-05-19T22:45:33+00:00 hourly 0.9 https://trial.medpath.com/news/5a955057d0a889b9/eli-lilly-considers-5-9-billion-biomanufacturing-facility-in-houston 2025-05-19T21:45:54+00:00 hourly 0.9 https://trial.medpath.com/news/309620164728eced/oligo-factory-expands-capabilities-with-new-low-scale-synthesis-platform-for-therapeutic-and-diagnostic-development 2025-05-19T21:44:18+00:00 hourly 0.9 https://trial.medpath.com/news/ac255c9e3f447188/crispr-therapeutics-expands-into-sirna-therapies-with-95m-sirius-partnership-for-thromboembolic-disorders 2025-05-19T21:44:16+00:00 hourly 0.9 https://trial.medpath.com/news/5efbfedec0a0599a/persist-ai-raises-12m-series-a-launches-cloud-lab-to-revolutionize-pharmaceutical-formulation-development 2025-05-19T21:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/2424994543509b1a/breakthrough-in-platelet-engineering-opens-new-avenues-for-targeted-drug-delivery 2025-05-19T20:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/608f291dc3586e43/federal-circuit-ruling-opens-new-patent-challenge-avenue-for-life-sciences-companies 2025-05-19T20:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/889b3e434ab4c958/taiwan-to-expand-national-health-insurance-coverage-for-cancer-immunotherapies-and-targeted-drugs 2025-05-19T20:36:03+00:00 hourly 0.9 https://trial.medpath.com/news/fce4ac2b7642dc71/persist-ai-secures-12m-series-a-funding-to-revolutionize-pharmaceutical-formulation-development 2025-05-19T20:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/7c80a5faadb9ee6d/sarepta-therapeutics-revises-2025-guidance-following-elevidys-safety-event-and-operational-challenges 2025-05-19T20:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/4701a8fc0c6880a2/kriya-therapeutics-presents-promising-preclinical-data-for-kriya-825-gene-therapy-in-geographic-atrophy 2025-05-19T20:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/9c633d6e304a5e03/ucb-and-domino-data-lab-partner-to-modernize-statistical-computing-for-accelerated-drug-development 2025-05-19T20:16:33+00:00 hourly 0.9 https://trial.medpath.com/news/c207e0cb4d469bdb/nasa-awards-phase-ii-contract-to-yank-technologies-for-lunar-power-transmission-innovation 2025-05-19T20:16:17+00:00 hourly 0.9 https://trial.medpath.com/news/d762402b82026abe/arineta-s-spotlight-duo-ct-scanner-receives-fda-clearance-for-lung-cancer-screening 2025-05-19T20:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/1a703d925f305702/fda-s-approval-of-mrd-as-end-point-transforms-multiple-myeloma-research-and-treatment 2025-05-19T20:15:02+00:00 hourly 0.9 https://trial.medpath.com/news/8fa1db77264f18bb/k2-medical-research-launches-new-clinical-trials-program-in-rhode-island-focusing-on-alzheimer-s-disease 2025-05-19T20:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/7a00391ba030a758/ionis-reports-positive-phase-3-results-for-olezarsen-in-hypertriglyceridemia 2025-05-19T19:41:59+00:00 hourly 0.9 https://trial.medpath.com/news/17ffaf60ff5f2f72/ensifentrine-shows-promise-as-novel-monotherapy-and-add-on-treatment-for-copd 2025-05-19T19:41:52+00:00 hourly 0.9 https://trial.medpath.com/news/a3f699ef14a88a31/batura-trial-airsupra-reduces-severe-asthma-exacerbation-risk-by-47-compared-to-albuterol-alone 2025-05-19T19:40:17+00:00 hourly 0.9 https://trial.medpath.com/news/ca05d9dbfd08eca1/fda-expands-jivi-approval-for-hemophilia-a-treatment-in-children-ages-7-12 2025-05-19T18:45:28+00:00 hourly 0.9 https://trial.medpath.com/news/bf0fa0043048395e/fda-grants-orphan-drug-designation-to-repair-biotechnologies-mrna-therapy-for-rare-cholesterol-disorder 2025-05-19T18:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/9f67fda53a6bd155/gradient-s-pulmonary-artery-denervation-system-receives-fda-breakthrough-designation-for-pulmonary-hypertension 2025-05-19T17:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/adf5a9c0c34b1bb7/cellcentric-secures-120-million-series-c-funding-to-advance-oral-multiple-myeloma-treatment 2025-05-19T16:47:37+00:00 hourly 0.9 https://trial.medpath.com/news/3072292a5168c144/prime-medicine-restructures-ceo-replaced-25-staff-cut-and-lead-program-halted 2025-05-19T16:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/61d0fbd66514c0f5/gt-biopharma-advances-gtb-3650-phase-1-trial-to-second-cohort-following-promising-immune-activation-signals 2025-05-19T16:46:45+00:00 hourly 0.9 https://trial.medpath.com/news/6e037445d03d9a24/reunion-neuroscience-completes-patient-dosing-in-phase-2-trial-of-novel-psychedelic-for-postpartum-depression 2025-05-19T16:46:43+00:00 hourly 0.9 https://trial.medpath.com/news/0c9f2f36f89b93ae/respira-therapeutics-to-present-phase-2b-results-of-rt234-inhalation-therapy-for-pah-at-ats-2025 2025-05-19T16:46:39+00:00 hourly 0.9 https://trial.medpath.com/news/6fac5b0bc1ece2b4/eascra-biotech-secures-100000-massventures-grant-for-novel-nanoparticle-drug-delivery-platform 2025-05-19T16:44:35+00:00 hourly 0.9 https://trial.medpath.com/news/0aba202447b4bde6/juvena-therapeutics-initiates-first-in-human-trial-of-juv-161-for-muscle-regeneration-in-myotonic-dystrophy 2025-05-19T16:22:07+00:00 hourly 0.9 https://trial.medpath.com/news/74640e8d402e50b0/recludix-s-stat6-inhibitor-shows-promising-efficacy-in-preclinical-asthma-model-matching-biologic-treatments 2025-05-19T16:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/b8b9c51d153a5860/cordis-launches-10000-patient-global-registry-for-selution-slr-drug-eluting-balloon 2025-05-19T16:21:52+00:00 hourly 0.9 https://trial.medpath.com/news/c9583ae7917d5df1/appili-therapeutics-terminates-1m-acquisition-deal-with-aditxt-secures-loan-extensions 2025-05-19T16:21:31+00:00 hourly 0.9 https://trial.medpath.com/news/ba6219b64d2a9820/rani-therapeutics-and-chugai-pharmaceutical-partner-to-advance-oral-antibody-delivery-technology 2025-05-19T16:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/5b9acc7d6805a4d0/fujifilm-validates-novel-peptide-oligonucleotide-conjugates-for-targeted-cancer-cell-delivery 2025-05-19T16:20:11+00:00 hourly 0.9 https://trial.medpath.com/news/c8a38504296cdef0/prime-medicine-reports-breakthrough-clinical-data-for-first-prime-editing-therapy-in-chronic-granulomatous-disease 2025-05-19T16:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/13f7d1cc8559d41b/ainos-reports-promising-interim-results-for-veldona-in-feline-chronic-gingivostomatitis-treatment 2025-05-19T16:17:55+00:00 hourly 0.9 https://trial.medpath.com/news/a5522a2975cfa3b1/scientists-develop-successful-blood-vessel-implants-in-rats 2025-05-19T16:17:15+00:00 hourly 0.9 https://trial.medpath.com/news/f32e67914d039bbd/ruxoprubart-shows-promising-phase-ii-results-as-novel-monotherapy-for-paroxysmal-nocturnal-hemoglobinuria 2025-05-19T16:17:13+00:00 hourly 0.9 https://trial.medpath.com/news/56e60b07187aecbd/global-gvhd-clinical-trials-review-reveals-key-trends-and-strategic-opportunities-for-2025 2025-05-19T16:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/1bad0908c45a0966/gustave-roussy-launches-umbrella-trial-using-blood-based-tumor-dna-to-revolutionize-cancer-follow-up-care 2025-05-19T16:16:20+00:00 hourly 0.9 https://trial.medpath.com/news/0e5a3bf5b792d468/siscapa-and-biognosys-partner-to-advance-protein-biomarker-analysis-for-clinical-trials 2025-05-19T16:16:18+00:00 hourly 0.9 https://trial.medpath.com/news/c8767989b17d2055/robust-pipeline-of-50-therapies-reshaping-moderate-to-severe-atopic-dermatitis-treatment-landscape 2025-05-19T16:16:16+00:00 hourly 0.9 https://trial.medpath.com/news/3d5283ae35be739f/rejuvenate-biomed-initiates-phase-ii-trial-of-rjx-01-for-copd-related-muscle-weakness 2025-05-19T16:16:12+00:00 hourly 0.9 https://trial.medpath.com/news/02eb8ad7d46f49bd/surgical-robotics-advance-endoquest-and-virtuoso-begin-first-human-trials-for-minimally-invasive-procedures 2025-05-19T16:16:10+00:00 hourly 0.9 https://trial.medpath.com/news/c65c725ef3ab5f89/olaris-secures-strategic-investment-from-bruker-to-advance-metabolomics-diagnostic-platform 2025-05-19T16:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/94a824bdbcaf1707/stanford-researchers-develop-synthetic-molecule-that-targets-and-eliminates-breast-and-pancreatic-cancers 2025-05-19T16:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/5f8cde3fd0166d4f/teva-pharmaceutical-launches-2-billion-senior-notes-offering-to-restructure-debt 2025-05-19T15:11:37+00:00 hourly 0.9 https://trial.medpath.com/news/a6cd74173b207d96/acg-unveils-patented-personalized-capsule-machine-for-custom-supplement-formulation 2025-05-19T14:40:05+00:00 hourly 0.9 https://trial.medpath.com/news/28482dc5ef659e57/cytomx-doses-first-patient-in-combination-trial-of-cx-801-with-keytruda-for-metastatic-melanoma 2025-05-19T12:47:53+00:00 hourly 0.9 https://trial.medpath.com/news/ed8a893f5b05b6de/johnson-johnson-and-karolinska-institutet-celebrate-decade-of-collaboration-advancing-medical-innovations 2025-05-19T12:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/64ee0fe43d449afb/ab-science-secures-chinese-patent-for-masitinib-in-covid-19-treatment-until-2041 2025-05-19T12:47:18+00:00 hourly 0.9 https://trial.medpath.com/news/581723023a35f9c2/astellas-to-present-new-long-term-survival-data-for-cancer-therapies-at-asco-2025 2025-05-19T12:47:04+00:00 hourly 0.9 https://trial.medpath.com/news/e34f125fa53bda51/evolving-treatment-landscape-for-metastatic-hormone-sensitive-prostate-cancer-beyond-adt-monotherapy 2025-05-19T12:47:03+00:00 hourly 0.9 https://trial.medpath.com/news/ac567c7a6e2a94bc/ema-designates-allopurinol-as-first-orphan-drug-for-marfan-syndrome 2025-05-19T12:45:26+00:00 hourly 0.9 https://trial.medpath.com/news/3baad35e31e497f6/scientific-breakthrough-reveals-how-alpha1h-targets-bladder-cancer-cells 2025-05-19T12:44:41+00:00 hourly 0.9 https://trial.medpath.com/news/c10cca6150721a21/protagenic-and-phytanix-merge-to-form-neuroactive-biopharmaceutical-company-with-obesity-drug-in-development 2025-05-19T12:43:35+00:00 hourly 0.9 https://trial.medpath.com/news/e5350086a0d0bb07/dextech-medical-secures-european-patent-for-osteodex-gmp-manufacturing-until-2045 2025-05-19T12:12:43+00:00 hourly 0.9 https://trial.medpath.com/news/e8d6e635187027ee/taiwan-approves-chugai-s-piasky-as-first-subcutaneous-treatment-for-paroxysmal-nocturnal-hemoglobinuria 2025-05-19T12:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/3b198f5928159358/massalia-therapeutics-launches-with-seed-funding-to-target-fibrosis-neoplasm-neovascularization-interface 2025-05-19T12:11:43+00:00 hourly 0.9 https://trial.medpath.com/news/403e11e120e4c9db/regeneron-to-acquire-23andme-for-256-million-expanding-genetics-driven-drug-discovery-capabilities 2025-05-19T12:11:36+00:00 hourly 0.9 https://trial.medpath.com/news/6dda314c33071c0d/akantior-r-receives-uk-marketing-authorization-as-first-approved-treatment-for-acanthamoeba-keratitis 2025-05-19T12:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/4c65f680c8423993/fda-approves-18-new-personalized-medicines-in-2024-marking-significant-shift-in-treatment-paradigm 2025-05-19T12:11:25+00:00 hourly 0.9 https://trial.medpath.com/news/4fa7c555ea0d6b98/vesalius-real-study-reveals-critical-gaps-in-cardiovascular-care-despite-available-treatments 2025-05-19T12:11:15+00:00 hourly 0.9 https://trial.medpath.com/news/26d36380fb151f1c/merck-and-daiichi-sankyo-launch-phase-3-trial-of-novel-b7-h3-targeted-adc-for-advanced-esophageal-cancer 2025-05-19T12:11:11+00:00 hourly 0.9 https://trial.medpath.com/news/79b445fa72111641/taiwan-administers-first-alzheimer-s-drug-targeting-amyloid-plaques 2025-05-19T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a359462ccbb47591/cipla-receives-vai-status-from-usfda-for-two-manufacturing-facilities 2025-05-19T09:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/895f80fbad927efe/new-mainland-chinese-cancer-drug-shows-promising-results-in-phase-1-trial 2025-05-19T08:37:23+00:00 hourly 0.9 https://trial.medpath.com/news/226573b50ca9f48d/fda-rejects-immunitybio-s-expanded-anktiva-application-while-lifting-hold-on-atara-s-ebvallo-trials 2025-05-19T08:37:22+00:00 hourly 0.9 https://trial.medpath.com/news/242a2c5f9b4ed19f/eur13-6m-eu-funded-predi-lynch-project-aims-to-transform-cancer-screening-for-lynch-syndrome-patients 2025-05-19T08:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/e7e3782dff9a8055/azvudine-shows-comparable-effectiveness-to-nirmatrelvir-ritonavir-for-covid-19-patients-with-chronic-liver-disease 2025-05-19T08:37:07+00:00 hourly 0.9 https://trial.medpath.com/news/560ee5de9bfdaf41/immupharma-advances-p140-autoimmune-program-with-novel-non-immunosuppressive-mechanism 2025-05-19T08:36:16+00:00 hourly 0.9 https://trial.medpath.com/news/5ab1b0bd33b746c5/new-teletrial-model-brings-hope-to-severe-eczema-patients-in-regional-areas 2025-05-19T08:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/b1e61342b38c3fa9/sleep-disturbances-in-icu-patients-new-research-reveals-impact-on-recovery-and-outcomes 2025-05-19T04:35:25+00:00 hourly 0.9 https://trial.medpath.com/news/8b222ddd040ffa7e/india-s-corbevax-covid-19-vaccine-upgraded-from-emergency-use-to-full-drug-approval-for-ages-5-and-above 2025-05-19T04:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/bed857f446cdc21e/medicare-low-income-drug-subsidy-loss-linked-to-higher-mortality-rates 2025-05-19T04:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/2e6e8dee9090cb2c/weight-gain-combined-with-delayed-motherhood-nearly-triples-breast-cancer-risk-study-finds 2025-05-19T04:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/aa75a72e424ab5f1/wegovy-prescriptions-for-us-teens-surge-50-as-weight-loss-surgery-also-rises-despite-glp-1-drug-availability 2025-05-19T04:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/6004cdc9f221bf68/new-lung-allocation-system-reduces-waitlist-deaths-by-75-since-2023-implementation 2025-05-19T03:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/a7dffc5f840bb8a4/dupilumab-reduces-asthma-exacerbations-in-children-regardless-of-disease-duration 2025-05-19T02:36:27+00:00 hourly 0.9 https://trial.medpath.com/news/8d55254e5fe1f00e/former-president-biden-diagnosed-with-metastatic-prostate-cancer 2025-05-19T02:36:12+00:00 hourly 0.9 https://trial.medpath.com/news/e4cba29af2dc6dd5/fda-clears-brainstorm-cell-therapeutics-phase-3b-trial-of-nurown-for-als-treatment 2025-05-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b807cdc72443c388/post-marketing-safety-analysis-of-voclosporin-reveals-new-adverse-event-patterns-in-lupus-nephritis-treatment 2025-05-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a90f78714994f8fe/uc-davis-scientists-develop-non-hallucinogenic-lsd-derivative-that-shows-promise-for-schizophrenia-treatment 2025-05-18T22:36:46+00:00 hourly 0.9 https://trial.medpath.com/news/031ace3f9683d4eb/interpace-biosciences-secures-us-patent-for-microrna-technology-in-thyroid-cancer-diagnosis 2025-05-18T20:37:34+00:00 hourly 0.9 https://trial.medpath.com/news/65f7020011cd9af1/rhone-x-trial-faricimab-shows-sustained-4-year-benefits-with-reduced-injection-burden-in-dme-patients 2025-05-18T20:35:23+00:00 hourly 0.9 https://trial.medpath.com/news/ec214853ce553833/imvaria-presents-real-world-data-on-fda-authorized-ai-diagnostic-service-for-pulmonary-fibrosis-at-ats-2025 2025-05-18T16:35:53+00:00 hourly 0.9 https://trial.medpath.com/news/440662fb102d5e16/uk-government-announces-10-year-r-d-funding-initiative-to-boost-pharmaceutical-research 2025-05-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f5ce92badabca24f/scilex-publishes-gloperba-dosing-guidelines-for-gout-patients-with-kidney-impairment 2025-05-18T14:35:45+00:00 hourly 0.9 https://trial.medpath.com/news/f8c132223529caea/fecal-microbiota-therapy-shows-95-success-rate-in-preventing-recurrent-c-difficile-infection 2025-05-18T13:41:29+00:00 hourly 0.9 https://trial.medpath.com/news/3060209d2647f64a/fda-approves-novavax-covid-19-vaccine-with-restricted-use-for-high-risk-groups 2025-05-18T09:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/6ce14bd1c90e139b/cdsco-approves-astrazeneca-s-protocol-amendments-for-durvalumab-tremelimumab-combination-in-advanced-liver-cancer 2025-05-18T04:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/db6d26b3a35bd9f5/pfizer-receives-cdsco-approval-for-phase-3-trial-of-her2-targeting-adc-disitamab-vedotin 2025-05-18T04:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/d4ef9c1b5c741ff5/onco-dermatology-emerges-as-critical-component-of-multidisciplinary-cancer-care 2025-05-18T03:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/9d9d4e61ac849ee2/fda-accepts-sparsentan-snda-for-full-approval-in-focal-segmental-glomerulosclerosis 2025-05-18T03:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/daa9127d8ff593cd/stem-cell-transplant-maintains-cost-effective-role-despite-novel-multiple-myeloma-therapies 2025-05-18T02:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/3f3e2a91f0c8a805/usfda-issues-form-483-with-two-observations-for-dr-reddy-s-new-york-api-facility 2025-05-18T00:41:29+00:00 hourly 0.9 https://trial.medpath.com/news/d462665b7a2917f2/silo-pharma-secures-2-million-in-public-offering-to-advance-cns-and-pain-therapeutics 2025-05-18T00:40:51+00:00 hourly 0.9 https://trial.medpath.com/news/5e868b4d80333d24/long-acting-antiviral-cd388-shows-76-efficacy-against-flu-in-phase-3-trial 2025-05-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ba45d475f4a2af03/sylentis-reports-positive-phase-iia-results-for-syl1801-eye-drops-in-age-related-macular-degeneration 2025-05-17T20:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/09fb4b20f0a4d82b/alzheimer-s-drug-discovery-foundation-partners-with-siemens-healthineers-to-license-speechdx-dataset-for-speech-based-biomarker-development 2025-05-17T18:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/6a4db629ae4992c5/panjab-university-patents-breakthrough-green-nanomicelle-platform-for-pharmaceutical-and-skincare-applications 2025-05-17T16:41:52+00:00 hourly 0.9 https://trial.medpath.com/news/33da2871fb9dede3/brain-cancer-canada-funds-68000-for-innovative-dipg-vaccine-clinical-trial 2025-05-17T16:41:35+00:00 hourly 0.9 https://trial.medpath.com/news/b8e73cef7636df3a/kakao-healthcare-expands-ai-powered-glucose-monitoring-app-to-japanese-market 2025-05-17T16:41:30+00:00 hourly 0.9 https://trial.medpath.com/news/32910e78c2825aad/bgg-expands-world-s-largest-astaxanthin-facility-in-china-doubles-r-d-capacity 2025-05-17T16:41:14+00:00 hourly 0.9 https://trial.medpath.com/news/b26da3518de84ba0/trump-s-most-favored-nation-drug-pricing-policy-threatens-german-pharma-industry 2025-05-17T16:41:11+00:00 hourly 0.9 https://trial.medpath.com/news/be5091206ebe8ae0/black-women-face-disproportionate-advanced-stage-cancer-diagnoses-amid-growing-healthcare-access-barriers 2025-05-17T15:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/8fd19181ae0e4b5c/tessera-therapeutics-reports-breakthrough-gene-editing-results-for-multiple-genetic-diseases 2025-05-17T12:35:55+00:00 hourly 0.9 https://trial.medpath.com/news/985b20c828904bf4/pharmaceutical-grade-cannabidiol-shows-promising-cardiac-safety-profile-in-high-risk-patients 2025-05-17T12:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/c3d83a4be0e2bbaf/thermo-fisher-scientific-launches-cell-and-gene-therapy-vision-centre-in-south-korea-to-accelerate-advanced-therapeutic-development 2025-05-17T12:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/d30d1f7dcd2d0f09/el1ssar-trial-confirms-efficacy-of-atezolizumab-plus-nab-paclitaxel-in-pd-l1-positive-advanced-tnbc 2025-05-17T12:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/30d9a622c0013b38/fractyl-health-s-novel-smart-glp-1-gene-therapy-shows-promise-for-diabetes-and-obesity-treatment 2025-05-17T12:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/c307898398bb9872/eisai-s-remitoro-clears-post-marketing-surveillance-requirements-for-t-cell-lymphoma-treatment-in-japan 2025-05-17T12:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/1d013fb1d5848f61/ai-in-oncology-transforming-community-practice-from-patient-care-to-revenue-cycles 2025-05-17T10:36:04+00:00 hourly 0.9 https://trial.medpath.com/news/63e1024dcf500513/first-biologic-drug-for-pulmonary-sarcoidosis-in-50-years-administered-at-oxford-hospital 2025-05-17T08:36:15+00:00 hourly 0.9 https://trial.medpath.com/news/f762a60b17166aa4/fezolinetant-shows-promising-body-composition-benefits-for-menopausal-women-in-phase-3-trials 2025-05-17T08:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/1986149c8eab9cc1/cardioplexoltm-demonstrates-safety-and-efficacy-in-phase-3-trial-for-cardiac-surgery 2025-05-17T06:41:53+00:00 hourly 0.9 https://trial.medpath.com/news/f0a92c73e1b110df/fda-advisory-committee-rejects-urogen-s-bladder-cancer-therapy-ugn-102 2025-05-17T06:41:42+00:00 hourly 0.9 https://trial.medpath.com/news/c99131dae2ab8b5a/landmark-va-study-reveals-genomic-differences-in-metastatic-prostate-cancer-across-racial-groups 2025-05-17T04:39:38+00:00 hourly 0.9 https://trial.medpath.com/news/98dec5e86df6303d/sp-102-shows-clinically-meaningful-results-for-sciatica-treatment-in-clear-trial-analysis 2025-05-17T04:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/f9d9d330d250a5af/china-approves-first-domestically-developed-enzyme-replacement-therapy-for-gaucher-disease 2025-05-17T04:39:24+00:00 hourly 0.9 https://trial.medpath.com/news/d8826cab00fc2632/biacure-secures-2-6m-nih-grant-to-develop-novel-high-frequency-energy-treatment-for-onychomycosis 2025-05-17T04:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/d189778aac9b0b8c/resistance-mechanisms-drive-personalized-treatment-selection-after-osimertinib-failure-in-egfr-mutant-nsclc 2025-05-17T03:12:53+00:00 hourly 0.9 https://trial.medpath.com/news/edb50cb8ff8f7d2d/attr-cm-treatment-landscape-expands-with-three-fda-approved-disease-modifying-therapies 2025-05-17T02:40:59+00:00 hourly 0.9 https://trial.medpath.com/news/338fe7586fa681ff/abelzeta-s-c-car168-shows-promising-results-in-treating-refractory-lupus-nephritis-and-multiple-sclerosis 2025-05-17T02:40:32+00:00 hourly 0.9 https://trial.medpath.com/news/3599f2fc24f67b7d/alvotech-expands-european-presence-with-successful-nasdaq-stockholm-listing 2025-05-17T02:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/81d8fba1f3456619/endo-expands-adrenalin-r-ready-to-use-premixed-bag-line-with-new-8-mg-250-ml-concentration-for-septic-shock 2025-05-17T01:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/84df8af6a6aaf299/fda-deputy-commissioner-signals-potential-overhaul-of-pdufa-reauthorization-structure 2025-05-17T00:42:31+00:00 hourly 0.9 https://trial.medpath.com/news/e5c691d1c83b0522/remedy-plan-therapeutics-secures-18-million-to-advance-novel-nampt-inhibitor-for-aml-and-mds-treatment 2025-05-17T00:42:01+00:00 hourly 0.9 https://trial.medpath.com/news/0ad7299d753f35bc/federal-court-backs-hhs-in-340b-drug-pricing-dispute-with-major-pharmaceutical-companies 2025-05-17T00:41:56+00:00 hourly 0.9 https://trial.medpath.com/news/707ad2505e07beb6/amneal-pharmaceuticals-reports-strong-q1-2025-results-with-5-revenue-growth-and-margin-expansion 2025-05-17T00:41:47+00:00 hourly 0.9 https://trial.medpath.com/news/740525bebecf033e/izotropic-secures-fda-regulatory-alignment-for-izoview-breast-ct-system-advances-toward-pivotal-clinical-trial 2025-05-16T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/313a47856f531aaa/gan-lee-pharmaceuticals-partners-with-brazil-to-localize-insulin-production-in-landmark-agreement 2025-05-16T22:43:18+00:00 hourly 0.9 https://trial.medpath.com/news/ecba5b832166af1f/fda-recalls-nearly-76000-cases-of-eye-care-products-due-to-manufacturing-deviations 2025-05-16T22:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/d622414fa67ce0dd/brainomix-s-e-lung-ai-technology-validated-for-progressive-pulmonary-fibrosis-detection-in-boehringer-ingelheim-collaboration 2025-05-16T21:42:20+00:00 hourly 0.9 https://trial.medpath.com/news/c0c5851015e709db/revolution-medicines-advances-first-in-class-kras-g12d-molecular-glue-inhibitor-rmc-9805-with-novel-cyclophilin-a-mechanism 2025-05-16T21:41:26+00:00 hourly 0.9 https://trial.medpath.com/news/42c8807d00b05c51/moderna-advances-oncology-pipeline-with-first-dosing-in-phase-1-trial-of-novel-mrna-cancer-therapy 2025-05-16T20:40:23+00:00 hourly 0.9 https://trial.medpath.com/news/b557fbda78e78f21/denosumab-shows-promise-as-immune-modulator-in-breast-cancer-treatment 2025-05-16T20:40:15+00:00 hourly 0.9 https://trial.medpath.com/news/2653e13b348106ee/lamassu-biotech-partners-with-ohio-state-university-for-dual-species-acute-pancreatitis-treatment-development 2025-05-16T20:39:32+00:00 hourly 0.9 https://trial.medpath.com/news/4fb60a8ce9f57fc9/nice-extends-access-to-brineura-for-cln2-batten-disease-while-seeking-long-term-solution 2025-05-16T20:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/afb2f424d65f2fe1/novartis-receives-cdsco-approval-for-phase-iiib-trial-of-asciminib-in-chronic-myeloid-leukemia 2025-05-16T20:38:25+00:00 hourly 0.9 https://trial.medpath.com/news/49cbe706d19ad47b/biocon-plans-4500-crore-qip-to-reduce-debt-and-increase-biologics-stake 2025-05-16T20:38:22+00:00 hourly 0.9 https://trial.medpath.com/news/69a2aca3d5993c9d/biocardia-advances-cardiac-cell-therapy-toward-fda-and-pmda-submissions-despite-primary-endpoint-miss 2025-05-16T20:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/2e0830e8c83f035f/rosaline-trial-neoadjuvant-letrozole-entrectinib-shows-limited-efficacy-in-invasive-lobular-breast-cancer 2025-05-16T20:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/3ac5421dfea95b8d/cansino-s-inhaled-tb-booster-vaccine-advances-with-clinical-trial-approval-in-indonesia 2025-05-16T19:40:58+00:00 hourly 0.9 https://trial.medpath.com/news/9032e497bca89a94/align-technology-s-invisalign-palatal-expander-system-receives-nmpa-approval-in-china 2025-05-16T17:41:23+00:00 hourly 0.9 https://trial.medpath.com/news/e79d005f5333597f/skin-cancer-awareness-month-multimodal-approaches-and-prevention-strategies-highlighted-by-experts 2025-05-16T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f56f6f5af6c9a720/novo-nordisk-ceo-lars-fruergaard-jorgensen-to-step-down-after-eight-year-tenure 2025-05-16T16:50:30+00:00 hourly 0.9 https://trial.medpath.com/news/0b6f827cb5d2e24f/acquired-hemophilia-a-pipeline-expands-with-10-novel-therapies-in-development 2025-05-16T16:49:28+00:00 hourly 0.9 https://trial.medpath.com/news/851ac9a059086d35/acadia-pharmaceuticals-secures-patent-victory-for-parkinson-s-drug-nuplazid-until-2038 2025-05-16T16:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/57e5758c0c173da9/acadia-pharmaceuticals-wins-patent-infringement-case-against-aurobindo-for-parkinson-s-drug-nuplazid 2025-05-16T16:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/5fb6c5572f8049cd/neurogene-unveils-protocol-to-reverse-hlh-syndrome-associated-with-high-dose-aav-gene-therapy 2025-05-16T16:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/f43f230e09a7b981/acuitas-therapeutics-and-chop-pioneer-personalized-crispr-therapy-for-infant-with-urea-cycle-disorder 2025-05-16T16:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/74ee8630b5efd3c4/levothyroxine-trial-to-evaluate-cardiovascular-benefits-in-elderly-with-subclinical-hypothyroidism 2025-05-16T16:47:49+00:00 hourly 0.9 https://trial.medpath.com/news/bffc77677627b4dd/paratek-to-present-groundbreaking-clinical-data-on-nuzyra-for-ntm-and-cabp-at-ats-2025 2025-05-16T16:47:10+00:00 hourly 0.9 https://trial.medpath.com/news/a5f1b62a05c27e25/breakthrough-sirna-drug-sns812-for-covid-19-selected-for-prestigious-ats-2025-presentation 2025-05-16T16:47:07+00:00 hourly 0.9 https://trial.medpath.com/news/ecf1243f0a87e76f/bluesphere-bio-appoints-immunotherapy-pioneer-alan-korman-as-chief-scientific-officer 2025-05-16T16:46:40+00:00 hourly 0.9 https://trial.medpath.com/news/7208afeee712c0ad/fda-approves-sun-pharma-s-next-generation-led-blu-u-device-for-actinic-keratosis-treatment 2025-05-16T16:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/26b5b95dd74321c8/stanford-medicine-gene-therapy-skin-grafts-show-81-healing-rate-in-phase-3-epidermolysis-bullosa-trial 2025-05-16T16:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/bec5d3e661265256/mestastop-solutions-seeks-approval-for-phase-ii-trial-targeting-colorectal-cancer-metastasis 2025-05-16T16:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/aed125ff14b0b435/corrigendum-published-for-pragmatic-cluster-randomized-clinical-trial-in-endocrinology 2025-05-16T16:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/260c7c00bbd03cfe/iqvia-and-sarah-cannon-research-institute-partner-to-transform-global-oncology-clinical-trials 2025-05-16T16:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/23c355fcedce2a18/world-s-first-patient-receives-personalized-crispr-gene-editing-therapy-at-children-s-hospital-of-philadelphia 2025-05-16T16:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/5b2177fcbd89b128/first-european-patients-receive-accelerator-based-boron-neutron-capture-therapy-for-head-and-neck-cancer 2025-05-16T15:41:54+00:00 hourly 0.9 https://trial.medpath.com/news/821746968c9ec97e/cadence-and-medera-launch-asia-s-first-multi-centre-gene-therapy-trial-for-heart-failure-in-singapore 2025-05-16T13:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/17e3291e455171eb/biomarin-acquires-inozyme-pharma-for-270-million-adding-late-stage-enzyme-therapy-for-rare-genetic-disorder 2025-05-16T13:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/168d1bcc8916daaf/india-launches-fifth-round-of-pli-scheme-for-bulk-drug-manufacturing-to-reduce-import-dependence 2025-05-16T12:45:24+00:00 hourly 0.9 https://trial.medpath.com/news/55f0fece7a7c2754/once-weekly-secnidazole-shows-superior-efficacy-for-recurrent-bacterial-vaginosis-treatment 2025-05-16T12:44:19+00:00 hourly 0.9 https://trial.medpath.com/news/02a47cfb791e92eb/ethris-and-lonza-partner-to-develop-room-temperature-stable-spray-dried-mrna-vaccines 2025-05-16T12:44:09+00:00 hourly 0.9 https://trial.medpath.com/news/6419d8ea7db43b64/alectinib-plus-bevacizumab-shows-promising-results-in-first-line-treatment-of-alk-positive-nsclc 2025-05-16T12:43:28+00:00 hourly 0.9 https://trial.medpath.com/news/bdf6b4f7bd6cfa97/gh001-shows-promising-results-in-phase-2b-trial-for-treatment-resistant-depression 2025-05-16T12:42:20+00:00 hourly 0.9 https://trial.medpath.com/news/8c2cdd9987017938/novartis-receives-swiss-approval-for-first-malaria-treatment-designed-for-newborns-and-infants 2025-05-16T12:12:14+00:00 hourly 0.9 https://trial.medpath.com/news/08a9e38721201c41/landmark-study-confirms-liver-health-biomarker-ct1-predicts-cardiac-and-liver-outcomes 2025-05-16T11:41:09+00:00 hourly 0.9 https://trial.medpath.com/news/aef0c602578755da/riliprubart-shows-promise-in-cidp-treatment-with-significant-neurofilament-light-reduction 2025-05-16T09:41:24+00:00 hourly 0.9 https://trial.medpath.com/news/4979753fcb39eb97/rakovina-therapeutics-secures-4m-strategic-financing-to-advance-ai-powered-cancer-drug-discovery-platform 2025-05-16T09:41:08+00:00 hourly 0.9 https://trial.medpath.com/news/16210de1fd718718/inhaled-thc-cbd-combination-shows-superior-efficacy-for-acute-migraine-in-randomized-clinical-trial 2025-05-16T09:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/d67ff67134bdcb2f/biodesix-presents-new-data-showing-nodify-lung-r-tests-improve-pulmonary-nodule-management 2025-05-16T08:44:49+00:00 hourly 0.9 https://trial.medpath.com/news/b753510a4962d728/regeneron-wins-407-million-in-landmark-antitrust-case-against-amgen-over-pcsk9-drug-market 2025-05-16T08:44:34+00:00 hourly 0.9 https://trial.medpath.com/news/090c76e5bf31221c/avacta-s-pre-cision-technology-makes-toxic-chemotherapy-safer-and-more-effective 2025-05-16T08:44:01+00:00 hourly 0.9 https://trial.medpath.com/news/67ff934264f11d0a/medvital-secures-8-4-crore-pre-seed-funding-to-transform-wound-care-and-skin-regeneration-in-india 2025-05-16T08:43:15+00:00 hourly 0.9 https://trial.medpath.com/news/208cbb74bfe923d9/china-approves-xuanyuening-bireociclib-first-dual-indication-cdk-inhibitor-for-advanced-breast-cancer 2025-05-16T08:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/93705ec03113e28c/innate-pharma-s-novel-nk-cell-engager-iph6501-to-be-presented-at-eha-2025-congress 2025-05-16T07:40:40+00:00 hourly 0.9 https://trial.medpath.com/news/4e17fd0d216a1b73/senseonics-secures-75-million-in-funding-to-accelerate-eversense-365-cgm-launch 2025-05-16T06:35:23+00:00 hourly 0.9 https://trial.medpath.com/news/779822ada1b1bdfb/mindfulness-based-cognitive-therapy-shows-promise-for-treatment-resistant-depression 2025-05-16T06:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/3fb28683b3c5acc1/uro-1-s-surecore-biopsy-system-shows-significant-improvement-in-prostate-cancer-diagnostic-accuracy 2025-05-16T06:12:13+00:00 hourly 0.9 https://trial.medpath.com/news/88a7611658cb1464/lupin-receives-fda-approval-for-generic-rivaroxaban-tablets-for-thrombosis-prevention 2025-05-16T05:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/cbdfd83c1510a74b/camber-pharmaceuticals-launches-temozolomide-capsules-for-brain-cancer-treatment 2025-05-16T04:35:11+00:00 hourly 0.9 https://trial.medpath.com/news/88246f6bd03122e2/world-first-clinical-trial-ligo-3d-bioprinting-device-revolutionizes-wound-treatment-using-patient-s-own-cells 2025-05-16T04:14:41+00:00 hourly 0.9 https://trial.medpath.com/news/906da134c764f955/elevated-lipoprotein-a-linked-to-higher-risk-of-recurrent-cardiovascular-events-in-landmark-study 2025-05-16T02:44:32+00:00 hourly 0.9 https://trial.medpath.com/news/88fb5e194faaf663/tarlatamab-for-sclc-comprehensive-administration-protocol-and-patient-selection-guidelines 2025-05-16T02:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/52b1e9f59ace0737/eu-wide-health-technology-assessment-regulation-set-to-transform-drug-access-across-europe-starting-january-2025 2025-05-16T01:51:58+00:00 hourly 0.9 https://trial.medpath.com/news/32e272d160b6b5f5/datavant-acquires-aetion-to-create-end-to-end-real-world-evidence-platform 2025-05-16T01:12:19+00:00 hourly 0.9 https://trial.medpath.com/news/3504f34dbff79790/bausch-health-and-mylan-reach-settlement-agreement-over-generic-ibs-drug-patents 2025-05-16T00:44:32+00:00 hourly 0.9 https://trial.medpath.com/news/73c9ed994e8bbe0d/bendamustine-linked-to-car-t-cell-manufacturing-failures-in-large-b-cell-lymphoma-patients 2025-05-16T00:43:09+00:00 hourly 0.9 https://trial.medpath.com/news/22b0b5a27d650562/aptamer-group-secures-new-development-contracts-and-licensing-deal-for-synthetic-antibody-alternatives 2025-05-16T00:42:08+00:00 hourly 0.9 https://trial.medpath.com/news/9ccf497ae950f8bf/innovent-initiates-head-to-head-phase-3-trial-of-mazdutide-vs-semaglutide-for-obesity-with-fatty-liver-disease 2025-05-16T00:13:46+00:00 hourly 0.9 https://trial.medpath.com/news/334d1b0b3c2eaec6/breakthrough-therapies-set-to-transform-eosinophilic-esophagitis-treatment-landscape 2025-05-16T00:13:37+00:00 hourly 0.9 https://trial.medpath.com/news/4f90bb0c4889108f/fda-to-release-new-regulatory-framework-for-vaccine-makers-within-weeks 2025-05-16T00:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/abf811a5aa3834ee/agc-biologics-and-quell-therapeutics-partner-to-advance-t-regulatory-cell-therapies-for-immune-disorders 2025-05-16T00:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/6a2c3925f47bd032/medicines-discovery-catapult-expands-strategic-partnerships-to-accelerate-uk-drug-discovery-innovation 2025-05-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/00d5f15975b3ccc2/abbvie-and-gilead-secure-eu-approval-for-next-generation-hepatitis-c-therapies-targeting-treatment-resistant-patients 2025-05-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6c5933d5f7499d35/novel-soft-auditory-brainstem-implant-shows-promise-for-neurofibromatosis-type-2-patients 2025-05-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/75ce08854d351f3f/glp-1-receptor-agonists-show-significant-survival-benefits-in-diabetic-patients-after-heart-attack-pci 2025-05-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c7d49635fb348ae3/fda-launches-systematic-postmarket-chemical-review-program-to-enhance-food-safety 2025-05-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b98ef548761ac6f7/atara-biotherapeutics-secures-16-million-funding-to-advance-tab-cel-bla-approval 2025-05-15T22:41:27+00:00 hourly 0.9 https://trial.medpath.com/news/5e7a8628cdb63390/calcutta-high-court-overturns-patent-rejection-for-nicotine-aerosol-device-clarifies-public-health-exception-limits 2025-05-15T22:14:55+00:00 hourly 0.9 https://trial.medpath.com/news/246fd72bf592e48a/singapore-biotech-mirxes-achieves-1-billion-valuation-with-hong-kong-ipo-becomes-first-southeast-asian-unicorn 2025-05-15T21:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/4677b48fc4e6db1c/hengrui-pharmaceuticals-aims-to-raise-1-27-billion-in-hong-kong-ipo 2025-05-15T21:12:28+00:00 hourly 0.9 https://trial.medpath.com/news/ee2dd0d0c72547d2/genvivo-reports-promising-phase-1-data-for-gen2-and-preclinical-results-for-gen-1013-cancer-immunotherapies-at-asgct-2025 2025-05-15T20:47:15+00:00 hourly 0.9 https://trial.medpath.com/news/ea8e5e51a6b7dff5/sparx-biopharmaceutical-and-mitsubishi-tanabe-pharma-america-partner-on-novel-immune-cell-targeting-adc-program 2025-05-15T20:47:07+00:00 hourly 0.9 https://trial.medpath.com/news/48123c2aa66aef94/pulmatrix-to-divest-phase-2-ready-migraine-treatment-and-isperse-technology-ahead-of-cullgen-merger 2025-05-15T20:47:02+00:00 hourly 0.9 https://trial.medpath.com/news/2ead58867da76f56/abbott-s-freestyle-libre-cgm-system-reduces-cardiovascular-hospitalization-risk-in-diabetes-patients 2025-05-15T20:47:01+00:00 hourly 0.9 https://trial.medpath.com/news/ff473ee233a39978/affluent-medical-s-artus-device-shows-87-reduction-in-urinary-leakage-advances-to-pivotal-trial-phase 2025-05-15T20:45:04+00:00 hourly 0.9 https://trial.medpath.com/news/26ad58e957b75881/fda-grants-cancer-drug-approvals-to-abbvie-and-msd-abbvie-announces-335m-adarx-partnership 2025-05-15T20:44:31+00:00 hourly 0.9 https://trial.medpath.com/news/f188b889e2b859f0/redica-systems-secures-new-financing-to-enhance-ai-driven-quality-intelligence-in-life-sciences 2025-05-15T20:44:20+00:00 hourly 0.9 https://trial.medpath.com/news/454969328ad30716/uva-health-develops-breakthrough-non-invasive-ultrasound-treatment-for-cerebral-cavernous-malformations 2025-05-15T20:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/8672424c3e204755/breakthrough-first-personalized-mrna-based-crispr-therapy-successfully-treats-infant-with-rare-metabolic-disorder 2025-05-15T20:14:06+00:00 hourly 0.9 https://trial.medpath.com/news/ecb508c983861bb5/eli-lilly-partners-with-rznomics-in-1-3b-deal-to-develop-rna-editing-therapy-for-hereditary-hearing-loss 2025-05-15T20:14:04+00:00 hourly 0.9 https://trial.medpath.com/news/501ce384a673282a/critical-limb-ischemia-market-projected-to-reach-2-5-billion-by-2035-driven-by-novel-therapies-and-advanced-diagnostics 2025-05-15T20:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/32190a12b82fd7d1/forward-science-launches-periostom-fda-cleared-chitosan-based-wound-dressing-for-periodontal-care 2025-05-15T20:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/e7d2328b7f30971a/abm-respiratory-care-launches-home-study-of-biwaze-clear-system-for-bronchiectasis-patients 2025-05-15T20:13:01+00:00 hourly 0.9 https://trial.medpath.com/news/5cec169b57144d4c/uk-launches-pilot-program-for-diversity-plans-in-drug-and-medical-device-trials 2025-05-15T20:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/782fafe9a6d205c4/hiv-vaccine-breakthrough-clinical-trials-show-promise-for-broadly-neutralizing-antibody-development 2025-05-15T20:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/b0070862101eea29/upc-issues-landmark-ruling-on-second-medical-use-patents-in-cholesterol-drug-dispute 2025-05-15T19:14:32+00:00 hourly 0.9 https://trial.medpath.com/news/66503e7aefc25e8b/elix-and-prism-biolab-form-strategic-partnership-for-ai-driven-drug-discovery 2025-05-15T18:41:15+00:00 hourly 0.9 https://trial.medpath.com/news/4030a9bf73bc9437/peptisystems-and-asahi-kasei-bioprocess-america-form-strategic-partnership-to-revolutionize-peptide-manufacturing 2025-05-15T18:14:31+00:00 hourly 0.9 https://trial.medpath.com/news/da32eadc7821c8d1/colorectal-cancer-leads-in-real-world-data-volume-but-oncology-trials-need-modernization 2025-05-15T17:44:30+00:00 hourly 0.9 https://trial.medpath.com/news/cebd65c219cbffe7/crispr-gene-editing-breakthrough-saves-baby-with-ultra-rare-metabolic-disorder 2025-05-15T17:43:13+00:00 hourly 0.9 https://trial.medpath.com/news/8b8224f2794ed488/new-study-shows-taf-and-dolutegravir-superior-for-second-line-hiv-treatment-in-children 2025-05-15T17:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/e9d8bc6b5a3b3081/agilent-and-ubix-therapeutics-form-5-year-partnership-to-advance-targeted-cancer-therapies-in-south-korea 2025-05-15T16:45:57+00:00 hourly 0.9 https://trial.medpath.com/news/a44b3b972bc02108/breakthrough-gene-editing-therapy-successfully-treats-infant-with-rare-metabolic-disorder 2025-05-15T16:43:43+00:00 hourly 0.9 https://trial.medpath.com/news/dd2839d100c962c7/klothea-bio-and-healthy-longevity-clinic-partner-to-advance-mrna-based-klotho-therapies-for-aging 2025-05-15T16:43:42+00:00 hourly 0.9 https://trial.medpath.com/news/5894cc5e9ca0d5f1/biomea-fusion-s-bmf-500-shows-promising-results-in-relapsed-refractory-acute-leukemia-phase-i-trial 2025-05-15T16:43:29+00:00 hourly 0.9 https://trial.medpath.com/news/52511bc37268ea09/genflow-biosciences-advances-sirt6-patent-applications-in-europe-and-japan-for-age-related-disease-therapies 2025-05-15T16:42:50+00:00 hourly 0.9 https://trial.medpath.com/news/742caf28a2714730/upc-sets-precedent-in-first-second-medical-use-patent-ruling-sanofi-and-regeneron-lose-against-amgen 2025-05-15T16:42:48+00:00 hourly 0.9 https://trial.medpath.com/news/a86cec338b118e58/ukraine-adopts-bolar-rule-to-accelerate-generic-drug-market-entry 2025-05-15T16:42:20+00:00 hourly 0.9 https://trial.medpath.com/news/faaef74eba4b0024/orna-therapeutics-demonstrates-promising-results-for-in-vivo-car-therapy-in-autoimmune-diseases 2025-05-15T16:41:41+00:00 hourly 0.9 https://trial.medpath.com/news/ee710a7d40993b61/intermountain-health-pioneers-first-remote-car-t-cell-collection-site-in-southern-utah 2025-05-15T16:41:39+00:00 hourly 0.9 https://trial.medpath.com/news/600a0f5e04aec254/rybodyn-expands-collaboration-with-moffitt-cancer-center-to-advance-novel-dark-proteome-cancer-immunotherapies 2025-05-15T16:41:37+00:00 hourly 0.9 https://trial.medpath.com/news/afbd5261237248b0/sona-nanotech-s-gold-nanorods-pass-critical-endotoxin-testing-ahead-of-first-human-cancer-trial 2025-05-15T16:41:30+00:00 hourly 0.9 https://trial.medpath.com/news/cd98fd66c9637d4d/alamar-biosciences-revolutionizes-alzheimer-s-detection-with-blood-based-brain-derived-tau-assays 2025-05-15T16:41:09+00:00 hourly 0.9 https://trial.medpath.com/news/ec0904bef42693f8/kincell-bio-secures-22-million-investment-to-expand-cell-therapy-manufacturing-capabilities 2025-05-15T16:40:46+00:00 hourly 0.9 https://trial.medpath.com/news/08e414cf49b16092/steerlife-unveils-solvent-free-melt-fusion-technology-for-potent-drug-development 2025-05-15T16:39:57+00:00 hourly 0.9 https://trial.medpath.com/news/fce2253cec7e891e/ema-s-pdco-endorses-poltreg-s-pediatric-investigation-plan-for-novel-type-1-diabetes-cell-therapy 2025-05-15T16:38:02+00:00 hourly 0.9 https://trial.medpath.com/news/7db6b1c586323497/elucent-medical-s-envisio-x1-surgical-navigation-system-receives-fda-breakthrough-device-designation 2025-05-15T16:11:49+00:00 hourly 0.9 https://trial.medpath.com/news/12c9d1fd2704626f/pathos-ai-raises-365-million-to-advance-ai-driven-oncology-drug-development 2025-05-15T16:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/c0ecc803f96478a4/optymedge-unveils-first-dedicated-ophthalmology-clinical-trial-platform-at-arvo-2025 2025-05-15T16:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/5a8d106c25542bce/pharmala-biotech-unveils-phenesafe-ai-platform-to-accelerate-mdxx-drug-discovery 2025-05-15T16:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/ca6a8b4064a622ce/fda-approves-brekiya-first-dhe-autoinjector-for-acute-migraine-and-cluster-headache-treatment 2025-05-15T16:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/e8cc2f07b0e03879/first-u-s-patient-dosed-in-moderna-s-phase-1-trial-of-novel-mrna-4106-pan-tumor-therapy 2025-05-15T16:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/c3af34384d061c18/biovie-initiates-phase-2-trial-of-bezisterim-for-long-covid-neurological-symptoms 2025-05-15T16:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/504e9bbc95f2bb48/regulatory-immune-cells-emerge-as-key-therapeutic-targets-in-immunotherapy-and-autoimmune-disease-treatment 2025-05-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/09833fe389b6a8d2/shilpa-medicare-receives-usfda-clearance-for-bengaluru-manufacturing-unit 2025-05-15T14:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/3eaacbdf23d2cf33/bendigo-patient-first-in-australia-to-trial-novel-prostate-cancer-drug-that-could-delay-chemotherapy 2025-05-15T13:42:09+00:00 hourly 0.9 https://trial.medpath.com/news/ee1c1a2ed11de3a2/broad-institute-selects-argonaut-to-manufacture-sirna-therapeutic-for-pioneering-prion-disease-trial 2025-05-15T13:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/b38a466192288d3f/samuraciclib-shows-promise-in-hr-breast-cancer-patients-without-tp53-mutations-or-liver-metastases 2025-05-15T12:40:25+00:00 hourly 0.9 https://trial.medpath.com/news/6122b684f8125260/european-consortium-secures-eur2-5-million-to-develop-predictive-biomarker-test-for-immunotherapy-response 2025-05-15T12:40:24+00:00 hourly 0.9 https://trial.medpath.com/news/7668ed7e8b26d6e0/imprint-labs-secures-15m-to-decode-immune-memory-for-chronic-disease-research 2025-05-15T12:40:16+00:00 hourly 0.9 https://trial.medpath.com/news/cf7a4928f11072bc/viva-biotech-unveils-ai-driven-drug-discovery-platform-promising-to-cut-development-time-by-50-70 2025-05-15T12:40:04+00:00 hourly 0.9 https://trial.medpath.com/news/1b61bc7a9e8e24f5/quralis-secures-exclusive-license-for-novel-rna-targeted-therapy-in-fragile-x-syndrome 2025-05-15T12:11:08+00:00 hourly 0.9 https://trial.medpath.com/news/2f1227faa6b39037/amt-bridle-pro-r-significantly-reduces-feeding-tube-dislodgement-in-pediatric-patients-study-finds 2025-05-15T12:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/ec049cf7d150de3b/immusoft-reports-breakthrough-results-from-first-ever-engineered-b-cell-therapy-in-mps-i-clinical-trial 2025-05-15T11:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/df2ba0acc7346d19/nutriband-advances-aversa-fentanyl-patch-development-through-strategic-partnership-with-kindeva-drug-delivery 2025-05-15T11:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/20a872ee97dee6a3/imu-biosciences-partners-with-curiox-for-uk-s-largest-immune-profiling-initiative 2025-05-15T10:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/87028ce7fc160be1/beigene-to-present-extensive-hematology-data-at-eha-2025-showcasing-brukinsa-and-next-generation-therapies 2025-05-15T10:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/cd1f1149ef12c42a/narmafotinib-combination-shows-superior-response-in-pancreatic-cancer-accent-trial 2025-05-15T10:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/c7aa4d83ae108f0d/lava-therapeutics-reports-q1-2025-results-while-restructuring-operations-and-advancing-clinical-trials 2025-05-15T10:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/780d62b480696cb2/jade-biosciences-advances-jade101-anti-april-antibody-for-iga-nephropathy-with-300m-funding 2025-05-15T09:41:32+00:00 hourly 0.9 https://trial.medpath.com/news/34a46de1f9d702c3/zeno-power-secures-50m-series-b-to-scale-nuclear-battery-production-for-defense-and-space-applications 2025-05-15T09:12:49+00:00 hourly 0.9 https://trial.medpath.com/news/715d1eb0b11854fd/median-technologies-submits-fda-510-k-application-for-ai-powered-lung-cancer-screening-software 2025-05-15T09:11:53+00:00 hourly 0.9 https://trial.medpath.com/news/3a1b310e6c50aeaf/sail-biomedicines-advances-novel-in-vivo-erna-car-t-therapy-for-autoimmune-diseases 2025-05-15T09:11:46+00:00 hourly 0.9 https://trial.medpath.com/news/2e465e1723b86ca2/nice-approves-capivasertib-fulvestrant-combination-for-advanced-breast-cancer-treatment 2025-05-15T08:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/29b1023c63993395/moderna-s-uk-mrna-vaccine-facility-now-fully-operational-in-oxfordshire 2025-05-15T08:39:53+00:00 hourly 0.9 https://trial.medpath.com/news/d1ad47c332fdf295/foresee-pharmaceuticals-initiates-phase-2-windward-trial-of-mirivadelgat-for-ph-ild-treatment 2025-05-15T08:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/058e373b9db0b245/immunofoco-unveils-novel-in-vivo-car-t-platform-with-enhanced-targeting-and-efficacy-at-asgct-2025 2025-05-15T08:39:44+00:00 hourly 0.9 https://trial.medpath.com/news/07b56dd3893a3f3c/liver-cirrhosis-pipeline-shows-strong-growth-with-30-therapies-in-development-across-multiple-clinical-phases 2025-05-15T08:39:34+00:00 hourly 0.9 https://trial.medpath.com/news/04c9308eab979932/onemeta-and-invictus-bpo-form-strategic-partnership-to-revolutionize-multilingual-customer-service 2025-05-15T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/e8327cd6e1a5b401/enedra-therapeutics-secures-new-funding-to-advance-ai-driven-platform-for-difficult-to-treat-cancers 2025-05-15T08:14:46+00:00 hourly 0.9 https://trial.medpath.com/news/43f57e13252d8465/weight-regain-after-stopping-glp-1-drugs-occurs-within-two-years-oxford-study-reveals 2025-05-15T06:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/c94e782ee6bb4e07/voyager-therapeutics-publishes-breakthrough-research-on-alpl-mediated-blood-brain-barrier-transport-for-gene-therapy 2025-05-15T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/04a67dcef3163ed1/schrodinger-to-present-phase-1-data-on-malt1-inhibitor-sgr-1505-for-relapsed-refractory-b-cell-malignancies 2025-05-15T03:13:23+00:00 hourly 0.9 https://trial.medpath.com/news/a12f423490f41d18/trump-administration-s-drug-pricing-order-targets-glp-1-market-threatening-novo-nordisk-and-eli-lilly-dominance 2025-05-15T02:42:22+00:00 hourly 0.9 https://trial.medpath.com/news/1a01c61485ba15c0/telisotuzumab-vedotin-plus-osimertinib-shows-promise-in-tki-resistant-nsclc-with-c-met-overexpression 2025-05-15T02:42:13+00:00 hourly 0.9 https://trial.medpath.com/news/3bd649b4253ffb0c/contineum-therapeutics-on-track-for-key-clinical-milestones-with-pipe-791-and-pipe-307-programs 2025-05-15T02:42:05+00:00 hourly 0.9 https://trial.medpath.com/news/2862881b3933c93c/bispecific-antibodies-show-superior-safety-profile-and-efficacy-in-follicular-lymphoma-treatment 2025-05-15T02:41:31+00:00 hourly 0.9 https://trial.medpath.com/news/bf2c6ae290f7afa3/neoadjuvant-immunotherapy-emerges-as-promising-strategy-for-early-stage-nsclc-treatment 2025-05-15T02:40:09+00:00 hourly 0.9 https://trial.medpath.com/news/00439ae578d06c2c/nationwide-study-confirms-safety-of-lumason-r-ultrasound-enhancing-agent-in-echocardiography 2025-05-15T02:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/c5b05586566ee166/inozyme-s-inz-701-shows-promise-in-enpp1-deficiency-trial-with-sustained-phosphate-increases 2025-05-15T02:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/c59000d121c1efc2/ntxbio-to-establish-31m-biomanufacturing-facility-in-plano-texas-creating-170-jobs 2025-05-15T02:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/c236a1e1f7e8359b/julius-clinical-and-peachtree-bioresearch-solutions-merge-to-create-global-cro-with-enhanced-cns-capabilities 2025-05-15T01:38:52+00:00 hourly 0.9 https://trial.medpath.com/news/caad6d6e7274e11d/novel-nanoparticle-technology-enhances-ultrasound-cancer-treatment-while-reducing-collateral-damage 2025-05-15T01:38:28+00:00 hourly 0.9 https://trial.medpath.com/news/4bf759dc387c5e90/california-proposes-cutting-medi-cal-coverage-for-weight-loss-drugs-to-address-budget-deficit 2025-05-15T00:40:55+00:00 hourly 0.9 https://trial.medpath.com/news/8d077bc74ea460b4/yale-study-shows-nasal-vaccine-boosters-effective-without-adjuvants-for-respiratory-disease-protection 2025-05-15T00:40:43+00:00 hourly 0.9 https://trial.medpath.com/news/5cb9a58eb530c96f/trilink-biotechnologies-and-ivi-partner-to-advance-mrna-vaccine-development-for-global-health-equity 2025-05-15T00:40:15+00:00 hourly 0.9 https://trial.medpath.com/news/00752b26f723883f/apimeds-pharmaceuticals-raises-13-5m-in-nyse-american-ipo 2025-05-15T00:40:04+00:00 hourly 0.9 https://trial.medpath.com/news/5b607beac7564ed3/aspen-neuroscience-advances-automated-manufacturing-of-ipsc-derived-therapy-for-parkinson-s-disease 2025-05-15T00:39:14+00:00 hourly 0.9 https://trial.medpath.com/news/3ced6a5606e62c78/takeda-s-oveporexton-shows-promising-results-in-phase-2b-trial-for-narcolepsy-type-1 2025-05-15T00:14:38+00:00 hourly 0.9 https://trial.medpath.com/news/e891efb2cb3e8350/congenital-hyperinsulinism-pipeline-shows-promise-with-multiple-therapies-advancing-through-clinical-development 2025-05-15T00:14:27+00:00 hourly 0.9 https://trial.medpath.com/news/5471fa2ee2067dc2/chugai-seeks-approval-for-tecentriq-to-treat-rare-thymic-carcinoma-in-japan 2025-05-15T00:12:37+00:00 hourly 0.9 https://trial.medpath.com/news/2b8c8e37c82a5bfb/lenalidomide-plus-pd-1-inhibitor-achieves-sustained-remission-in-relapsed-hodgkin-lymphoma-case 2025-05-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/144ffbc3368d7bcd/intratumoral-microbiota-emerges-as-key-player-in-cancer-development-and-treatment-response 2025-05-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2029e8e969956403/federal-court-upholds-alexion-patent-blocks-amgen-biosimilar 2025-05-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/012335fe7fe64b4f/heidelberg-pharma-initiates-phase-i-trial-of-hdp-102-for-non-hodgkin-lymphoma-as-second-amanitin-based-adc-enters-clinic 2025-05-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/91858490c0f0fe52/genentech-advances-prasinezumab-to-phase-iii-for-early-stage-parkinson-s-disease-following-positive-phase-iib-results 2025-05-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cfafc9f08796ce25/ecolab-life-sciences-launches-advanced-bioprocessing-applications-lab-in-pennsylvania 2025-05-14T23:41:37+00:00 hourly 0.9 https://trial.medpath.com/news/b3a1917ffc33a1ce/nuvig-therapeutics-initiates-phase-2-trial-of-novel-cidp-treatment-nvg-2089 2025-05-14T23:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/3da0d443d1d07412/bioinvent-reports-promising-results-from-triple-combination-therapy-for-non-hodgkin-s-lymphoma 2025-05-14T21:44:19+00:00 hourly 0.9 https://trial.medpath.com/news/e263540832d23737/atyr-pharma-advances-novel-anti-fibrotic-therapy-atyr0101-for-pulmonary-fibrosis 2025-05-14T21:43:09+00:00 hourly 0.9 https://trial.medpath.com/news/a53c7d01e03a0fdf/plasmidsaurus-unveils-three-day-aav-genome-sequencing-service-to-transform-gene-therapy-development 2025-05-14T21:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/ae7d71054864da7b/autonomix-medical-to-expand-cancer-pain-management-trial-beyond-pancreatic-cancer-in-q2-2025 2025-05-14T20:44:45+00:00 hourly 0.9 https://trial.medpath.com/news/b00dfbf5c611a2db/qihan-biotech-unveils-novel-cytokine-pathway-engineering-for-enhanced-car-t-therapy-without-lymphodepletion 2025-05-14T20:43:50+00:00 hourly 0.9 https://trial.medpath.com/news/0d08c48d5aeeb229/eyecool-therapeutics-reports-positive-results-for-novel-cooling-device-to-treat-chronic-ocular-surface-pain 2025-05-14T20:43:04+00:00 hourly 0.9 https://trial.medpath.com/news/18c9ef1197993c5b/ibrutinib-nivolumab-combination-shows-promising-77-8-response-rate-in-relapsed-cns-lymphoma-trial 2025-05-14T20:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/3e04b4ef7abcf169/ernexa-therapeutics-expands-operations-with-texas-subsidiary-to-advance-ovarian-cancer-cell-therapy 2025-05-14T20:42:48+00:00 hourly 0.9 https://trial.medpath.com/news/c98d700e4c81223b/incyte-to-pay-novartis-280m-in-settlement-over-jakafi-royalty-dispute 2025-05-14T20:41:34+00:00 hourly 0.9 https://trial.medpath.com/news/5a9a71e126c87972/bioinvent-s-bi-1808-shows-promising-results-in-phase-2a-ctcl-trial-with-50-response-rate 2025-05-14T20:41:26+00:00 hourly 0.9 https://trial.medpath.com/news/e88eac102b9e0e2f/genmab-to-present-extensive-epcoritamab-clinical-data-at-2025-european-hematology-association-congress 2025-05-14T20:15:07+00:00 hourly 0.9 https://trial.medpath.com/news/f67d49d37ca897ea/elective-nodal-radiotherapy-shows-superior-metastasis-free-survival-in-oligorecurrent-prostate-cancer 2025-05-14T20:15:02+00:00 hourly 0.9 https://trial.medpath.com/news/0ec4a093dd4e6b06/fda-approves-belzutifan-as-first-oral-treatment-for-advanced-pheochromocytoma-and-paraganglioma 2025-05-14T20:13:47+00:00 hourly 0.9 https://trial.medpath.com/news/80a83b6bf48f139d/us-orphan-drug-market-set-to-exceed-190-billion-by-2030-as-fda-designations-accelerate 2025-05-14T20:13:34+00:00 hourly 0.9 https://trial.medpath.com/news/7826c621578925bb/breakthrough-first-successful-stem-cell-transplant-using-deceased-donor-for-blood-cancer-treatment 2025-05-14T20:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/4466463cec7d139c/novel-aav-capsid-shows-unprecedented-brain-transduction-potential-for-gene-therapy 2025-05-14T19:46:42+00:00 hourly 0.9 https://trial.medpath.com/news/a5b7823eee5299d9/merck-kgaa-joins-peregrine-ventures-incentive-incubator-as-strategic-partner 2025-05-14T19:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/e28cbd6ddc69c363/gsk-and-novartis-complete-16-billion-asset-swap-deal-reshaping-both-companies-strategic-focus 2025-05-14T19:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/026a171f6cd0c858/ispe-celebrates-20th-anniversary-with-announcement-of-2025-facility-of-the-year-awards-winners 2025-05-14T18:42:07+00:00 hourly 0.9 https://trial.medpath.com/news/4d94a99dd068dd88/arcellx-s-anito-cel-shows-97-response-rate-in-pivotal-multiple-myeloma-trial 2025-05-14T17:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/39b4e7b247e90138/surrozen-secures-key-patent-for-antibody-based-wnt-pathway-modulators-with-potential-in-retinal-disease-treatment 2025-05-14T16:45:17+00:00 hourly 0.9 https://trial.medpath.com/news/a79cab7e3793d9be/bruker-and-10x-genomics-end-patent-disputes-with-global-settlement-and-cross-license-agreements 2025-05-14T16:45:12+00:00 hourly 0.9 https://trial.medpath.com/news/14a913b5a06b64f9/autolus-reports-promising-long-term-data-for-obe-cel-in-relapsed-refractory-b-all-at-eha-congress 2025-05-14T16:45:06+00:00 hourly 0.9 https://trial.medpath.com/news/0c82d13e20889c56/five-promising-therapeutic-candidates-in-parkinson-s-disease-clinical-pipeline 2025-05-14T16:43:10+00:00 hourly 0.9 https://trial.medpath.com/news/5dd9c04d66e1fe51/thiogenesis-launches-phase-2-trial-of-tti-0102-for-melas-a-rare-mitochondrial-disease 2025-05-14T16:43:03+00:00 hourly 0.9 https://trial.medpath.com/news/cf716128610b7408/novel-treatment-regimen-extends-myeloma-remission-by-seven-months-in-uk-clinical-trial 2025-05-14T16:42:58+00:00 hourly 0.9 https://trial.medpath.com/news/27c88966352ad9c1/atossa-s-z-endoxifen-shows-77-7-tumor-reduction-in-phase-2-breast-cancer-trial 2025-05-14T16:42:56+00:00 hourly 0.9 https://trial.medpath.com/news/75042633f145df6d/forge-biologics-partners-with-fractyl-health-to-manufacture-aav-for-novel-pancreatic-gene-therapy-targeting-obesity-and-type-2-diabetes 2025-05-14T16:42:33+00:00 hourly 0.9 https://trial.medpath.com/news/51d98611c7e08617/novel-gene-editing-therapy-shows-promise-for-rare-fatal-heart-disease-attr-cm 2025-05-14T16:41:53+00:00 hourly 0.9 https://trial.medpath.com/news/fdbc88053b098cd6/therini-bio-secures-39m-in-series-a-extension-to-advance-novel-fibrin-targeting-therapy-for-neurodegenerative-diseases 2025-05-14T16:41:46+00:00 hourly 0.9 https://trial.medpath.com/news/d90057a776b53a05/invivyd-challenges-fda-with-citizen-petition-to-prioritize-monoclonal-antibodies-for-covid-19-prevention 2025-05-14T16:41:43+00:00 hourly 0.9 https://trial.medpath.com/news/7e464a93464c1adc/breakthrough-in-targeted-drug-delivery-novel-bacteriophage-loaded-wound-dressings-show-promise-for-chronic-infections 2025-05-14T16:41:16+00:00 hourly 0.9 https://trial.medpath.com/news/2c13db34e7b8ef02/abbvie-and-adarx-form-335-million-collaboration-to-develop-next-generation-sirna-therapies 2025-05-14T16:41:15+00:00 hourly 0.9 https://trial.medpath.com/news/b195dadd25ab1932/iteos-and-gsk-halt-development-of-tigit-antibody-belrestotug-after-phase-ii-trial-failures-in-lung-and-head-neck-cancers 2025-05-14T16:11:29+00:00 hourly 0.9 https://trial.medpath.com/news/4b53448b5e200c99/renovaro-launches-augusta-ai-powered-platform-aims-to-transform-neurological-drug-discovery 2025-05-14T16:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/4574e4a6c06c9710/betterlife-pharma-s-betr-001-shows-promise-as-non-hallucinogenic-neuroplastogen-for-psychiatric-disorders 2025-05-14T16:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/521c0d81cb9446ae/channel-therapeutics-nav1-7-inhibitor-shows-promising-results-for-ocular-pain-in-preclinical-trials 2025-05-14T16:09:53+00:00 hourly 0.9 https://trial.medpath.com/news/3776ea4c6397f2ae/philips-and-polarean-expand-radiation-free-xenon-mri-technology-for-pediatric-lung-disease 2025-05-14T16:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/8a3f2a1ee31bbe66/first-generic-eltrombopag-launches-expanding-access-for-thrombocytopenia-and-aplastic-anemia-patients 2025-05-14T16:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/ad12e1bf0eebb20d/precision-medicine-breakthrough-shows-2-6-fold-survival-improvement-in-deadly-canine-cancer 2025-05-14T16:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/561cba81bdd65647/exosomes-emerge-as-dual-purpose-tools-in-cancer-from-drug-resistance-mechanisms-to-therapeutic-delivery-systems 2025-05-14T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2dc65f875223e121/brain-organoids-emerge-as-revolutionary-platform-for-alzheimer-s-disease-research-and-digital-twin-development 2025-05-14T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/31baf49f231988b9/national-cancer-centre-singapore-launches-40-clinical-trials-spanning-multiple-cancer-types 2025-05-14T14:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/8f8b9ff7438b2759/caplin-steriles-receives-usfda-approval-for-generic-haloperidol-decanoate-injection 2025-05-14T13:59:55+00:00 hourly 0.9 https://trial.medpath.com/news/6dc59eaa9be27ab4/incyte-settles-280-million-royalty-dispute-with-novartis-over-jakafi 2025-05-14T13:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/26443aef3bd02b72/novo-nordisk-and-septerna-partner-on-2-2-billion-deal-to-develop-oral-obesity-treatments 2025-05-14T13:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/a6dd4aca62c446f8/trump-administration-suspends-enforcement-of-mental-health-parity-rule-raising-concerns-over-treatment-access 2025-05-14T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/33aff10e33ad861b/arrive-ai-debuts-on-nasdaq-with-autonomous-delivery-technology-for-healthcare-applications 2025-05-14T12:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/e4e97021687ca677/ibl-international-and-grifols-form-strategic-partnership-to-advance-specialty-diagnostics-with-novel-biomarker-panels 2025-05-14T12:38:10+00:00 hourly 0.9 https://trial.medpath.com/news/35c024ae30b191cc/sun-pharma-increases-investment-in-us-based-pharmazz-to-expand-specialty-therapeutics-portfolio 2025-05-14T12:37:42+00:00 hourly 0.9 https://trial.medpath.com/news/9dece5236797be37/kaerus-bioscience-s-ker-0193-receives-fda-orphan-and-rare-pediatric-drug-designations-for-fragile-x-syndrome 2025-05-14T12:37:39+00:00 hourly 0.9 https://trial.medpath.com/news/bbea111edca6d32c/gsk-acquires-efimosfermin-alfa-from-boston-pharmaceuticals-in-2-billion-deal-for-liver-disease-treatment 2025-05-14T12:10:53+00:00 hourly 0.9 https://trial.medpath.com/news/a8826ab1b2c3f796/gsk-acquires-phase-iii-ready-liver-disease-therapy-in-2-billion-deal 2025-05-14T12:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/08ea67a562177747/yaqrit-bolsters-leadership-team-to-advance-late-stage-liver-disease-treatments 2025-05-14T12:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/991699961de726c8/cytokinetics-aficamten-shows-positive-results-in-maple-hcm-trial-for-hypertrophic-cardiomyopathy 2025-05-14T12:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/fee89aa74f7752d9/excision-biotherapeutics-showcases-promising-crispr-based-therapies-for-hbv-and-hsv-at-asgct-2025 2025-05-14T10:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/b529a9ccfb618c60/glucotrack-secures-ethical-approval-for-long-term-clinical-study-of-implantable-blood-glucose-monitor 2025-05-14T09:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/8277fdc7c2ca7951/novel-compound-shp1705-targets-circadian-clock-to-combat-aggressive-glioblastoma 2025-05-14T09:13:22+00:00 hourly 0.9 https://trial.medpath.com/news/3eb2ef2df0396cda/define-gps-trial-completes-enrollment-potential-paradigm-shift-in-interventional-cardiology 2025-05-14T08:36:08+00:00 hourly 0.9 https://trial.medpath.com/news/18316cfb2e29bbf1/genespire-presents-promising-dosing-data-for-first-in-human-gene-therapy-in-methylmalonic-acidemia 2025-05-14T08:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/19dee8ff62be41ab/gujarat-fdca-expands-pharmaceutical-quality-control-with-new-ahmedabad-testing-laboratory 2025-05-14T08:35:43+00:00 hourly 0.9 https://trial.medpath.com/news/1660b6f755b41e49/hansa-biopharma-s-imlifidase-shows-sustained-five-year-outcomes-in-kidney-transplant-recipients 2025-05-14T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/5947df60dab6723b/komodo-health-s-real-world-evidence-platform-powers-31-research-studies-at-ispor-2025 2025-05-14T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c6e60a225199e9a8/fda-clears-freespira-breathing-system-for-teens-with-anxiety-disorders-empr-com 2025-05-14T07:39:50+00:00 hourly 0.9 https://trial.medpath.com/news/9c5428d886b056af/gc-biopharma-expands-u-s-plasma-collection-network-with-fda-approval-of-calexico-facility 2025-05-14T07:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/acda913dc3f28e9e/bharat-biotech-subsidiary-launches-world-s-first-diva-marker-vaccine-for-lumpy-skin-disease 2025-05-14T07:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/4425d5853bc7a9d9/aeva-secures-50-million-strategic-investment-for-4d-lidar-technology-expansion 2025-05-14T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6fb34c68ab519f92/pico-snpwt-device-reduces-c-section-complications-by-50-and-cuts-healthcare-costs-by-728000-per-1000-patients 2025-05-14T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/87dc1a3e207d2ad6/gsk-acquires-efimosfermin-for-1-2-billion-to-target-steatotic-liver-disease 2025-05-14T06:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/416490d7be764806/intron-seeks-partners-to-repurpose-sal200-for-mrsa-nasal-decolonization-in-surgical-patients 2025-05-14T06:39:30+00:00 hourly 0.9 https://trial.medpath.com/news/7b49ed8573ab870d/beam-therapeutics-to-present-updated-beam-101-data-from-17-sickle-cell-disease-patients-at-eha-2025 2025-05-14T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/8595340b2c4a931e/titan-sgstm-stapler-shows-significant-reduction-in-post-operative-gerd-following-sleeve-gastrectomy 2025-05-14T06:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/bdd2a2d35fb35573/becton-dickinson-files-patent-infringement-lawsuit-against-baxter-over-infusion-pump-technology 2025-05-14T05:41:42+00:00 hourly 0.9 https://trial.medpath.com/news/fa35c427711eaee8/novo-holdings-invests-in-schott-poonawalla-to-strengthen-injectable-drug-packaging-capabilities-in-india 2025-05-14T04:35:35+00:00 hourly 0.9 https://trial.medpath.com/news/d1924a62951bf821/exelixis-initiates-phase-1-trial-of-xb628-a-novel-bispecific-nk-cell-engager-for-advanced-solid-tumors 2025-05-14T04:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/766a1d415dfee246/perfluorohexyloctane-shows-unprecedented-rapid-relief-for-dry-eye-disease-in-phase-4-study 2025-05-14T04:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/10c47f9c09d36eeb/nexalin-technology-strengthens-scientific-advisory-board-to-accelerate-alzheimer-s-research-with-novel-brain-stimulation-technology 2025-05-14T04:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/2727f10200469774/fda-approves-phase-2b-trial-for-adipose-derived-stem-cell-therapy-in-crohn-s-disease 2025-05-14T04:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/17e6f9f30a82a5c7/adphc-partners-with-astrazeneca-to-combat-copd-in-abu-dhabi 2025-05-14T04:10:42+00:00 hourly 0.9 https://trial.medpath.com/news/7c5110cdbba6e0bb/cipla-targets-fy26-growth-with-glp-1-entry-and-peptide-pipeline-despite-revlimid-headwinds 2025-05-14T04:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/e7b6818988945162/cellfe-and-made-scientific-partner-to-advance-non-viral-gene-editing-for-t-cell-therapies 2025-05-14T03:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/b299417f02e06205/novel-compound-sana-shows-promise-in-phase-1-clinical-trial-for-obesity-treatment-through-unique-thermogenesis-mechanism 2025-05-14T02:41:23+00:00 hourly 0.9 https://trial.medpath.com/news/4aa8b1211b7d0990/patient-centered-approaches-key-to-addressing-health-equity-and-disparities-experts-say 2025-05-14T02:41:12+00:00 hourly 0.9 https://trial.medpath.com/news/16b3c7f1c6430d22/api-appoints-dr-launa-aspeslet-as-chief-translational-officer-to-accelerate-canadian-life-sciences-commercialization 2025-05-14T02:40:29+00:00 hourly 0.9 https://trial.medpath.com/news/88bef586e63a28dd/ats-2025-conference-to-showcase-groundbreaking-pulmonary-research-and-patient-centered-initiatives 2025-05-14T02:40:04+00:00 hourly 0.9 https://trial.medpath.com/news/51f858f20ed34207/orchard-therapeutics-lenmeldy-shows-long-term-efficacy-in-treating-metachromatic-leukodystrophy-nejm-study-reveals 2025-05-14T01:41:51+00:00 hourly 0.9 https://trial.medpath.com/news/18708261a21e25d3/hcw-biologics-secures-5-million-in-follow-on-financing-to-advance-immunotherapy-pipeline 2025-05-14T01:41:50+00:00 hourly 0.9 https://trial.medpath.com/news/706d5d332647a00d/ensysce-biosciences-secures-patent-for-novel-opioid-use-disorder-treatment-pf9001 2025-05-14T01:14:05+00:00 hourly 0.9 https://trial.medpath.com/news/d4ef897c4a397ee0/altimmune-secures-100-million-credit-facility-to-advance-pemvidutide-development-for-mash-and-alcohol-related-disorders 2025-05-14T01:12:58+00:00 hourly 0.9 https://trial.medpath.com/news/99bbda5fa63ae02d/saint-louis-university-launches-phase-1-trial-for-investigational-west-nile-virus-vaccine 2025-05-14T00:37:47+00:00 hourly 0.9 https://trial.medpath.com/news/843052f8361d4106/meiragtx-unveils-breakthrough-gene-therapies-for-obesity-and-neurodegenerative-diseases-at-asgct-2025 2025-05-14T00:37:05+00:00 hourly 0.9 https://trial.medpath.com/news/7710aca9a61a2ce9/rgenta-therapeutics-unveils-rswitch-technology-for-precise-control-of-gene-therapy-expression 2025-05-14T00:36:39+00:00 hourly 0.9 https://trial.medpath.com/news/25f7d362b2b6ac61/azenta-and-form-bio-partner-to-accelerate-aav-gene-therapy-development-with-ai-powered-analysis 2025-05-14T00:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/866459f98e033847/circio-presents-enhanced-circvec-gene-therapy-data-showing-distinct-tissue-expression-patterns-at-asgct-2025 2025-05-14T00:36:34+00:00 hourly 0.9 https://trial.medpath.com/news/d09efb239c760096/fda-issues-warning-to-mayne-pharma-for-misleading-nextstellis-birth-control-safety-claims 2025-05-14T00:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/2a0868974fc8b0a6/comend-and-odylia-therapeutics-form-strategic-partnership-to-transform-rare-disease-drug-development-through-patient-driven-platform 2025-05-14T00:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/5ab205fdb88d95d3/nhia-and-roche-expand-partnership-to-reduce-cancer-treatment-costs-in-nigeria 2025-05-14T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/47324dd005f9e0bd/stairmed-achieves-clinical-milestone-with-invasive-brain-computer-interface-system-in-amputee-patient 2025-05-14T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/44bbe26d6f03f010/avadel-pharmaceuticals-appoints-susan-rodriguez-as-chief-operating-officer-to-drive-lumryz-commercial-expansion 2025-05-14T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/aa6a8029cffe1d86/ethris-and-lonza-partner-to-develop-room-temperature-stable-mrna-respiratory-vaccines 2025-05-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3f68be340c03f8d2/nanocarrier-technology-shows-promise-for-alzheimer-s-disease-treatment-by-overcoming-blood-brain-barrier 2025-05-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/828be44e5d9df528/adial-pharmaceuticals-receives-milestone-payment-as-adovate-launches-phase-1-trial-for-novel-asthma-therapy 2025-05-13T23:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/994d5157ad400517/stylus-medicine-emerges-with-85m-to-revolutionize-in-vivo-genetic-medicines 2025-05-13T22:39:37+00:00 hourly 0.9 https://trial.medpath.com/news/bfaff9baf764cadc/artiva-s-allonk-cell-therapy-shows-durable-response-in-lymphoma-patients-in-phase-1-2-trial 2025-05-13T22:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/01f0ea79c8d21404/real-world-study-confirms-bevacizumab-benefits-limited-to-high-risk-epithelial-ovarian-cancer-patients 2025-05-13T22:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/dc8fbd7c0699eeae/valinor-discovery-emerges-from-stealth-with-ai-platform-to-simulate-drug-efficacy-before-clinical-trials 2025-05-13T21:43:59+00:00 hourly 0.9 https://trial.medpath.com/news/5a16e59fc9732023/gensco-pharma-acquires-global-rights-to-rizafilm-and-rizaport-for-migraine-treatment 2025-05-13T21:42:11+00:00 hourly 0.9 https://trial.medpath.com/news/c75278051ea22c15/pluto-bio-secures-3-6m-to-expand-ai-powered-platform-for-drug-discovery 2025-05-13T21:42:07+00:00 hourly 0.9 https://trial.medpath.com/news/52ea24c16704e22e/astrazeneca-s-azd1390-enters-gbm-agile-trial-for-newly-diagnosed-glioblastoma-patients 2025-05-13T20:40:08+00:00 hourly 0.9 https://trial.medpath.com/news/b0aab0620f311d89/new-ultrasound-bioprinter-enables-non-invasive-3d-printing-inside-the-body 2025-05-13T20:39:33+00:00 hourly 0.9 https://trial.medpath.com/news/1dadeea45eadb644/anito-cel-shows-promise-as-novel-bcma-targeted-car-t-therapy-for-multiple-myeloma 2025-05-13T20:38:56+00:00 hourly 0.9 https://trial.medpath.com/news/dbd48f794ddde440/sonoma-biotherapeutics-strengthens-leadership-team-with-appointment-of-rajesh-krishnan-as-chief-technical-officer 2025-05-13T20:37:43+00:00 hourly 0.9 https://trial.medpath.com/news/4cea2ae2f1327231/bionxt-centralizes-r-d-operations-in-munich-to-accelerate-ms-drug-development 2025-05-13T20:37:40+00:00 hourly 0.9 https://trial.medpath.com/news/70c517403167972f/absci-doses-first-participants-in-phase-1-trial-of-ai-designed-anti-tl1a-antibody-for-ibd 2025-05-13T20:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/3f6ae4544a1baf18/caretech-human-secures-500000-to-advance-ai-powered-urological-monitoring-device-in-clinical-trials 2025-05-13T20:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/36f6ac87b17bd9a4/maryland-stem-cell-research-fund-allocates-18-million-to-advance-regenerative-medicine-research 2025-05-13T20:36:20+00:00 hourly 0.9 https://trial.medpath.com/news/412b9211cf876530/somite-ai-secures-47m-series-a-to-transform-cell-therapy-with-foundation-models 2025-05-13T20:36:03+00:00 hourly 0.9 https://trial.medpath.com/news/78f097cae9f1a269/china-approves-remegen-s-disitamab-vedotin-for-her2-positive-advanced-breast-cancer-with-liver-metastasis 2025-05-13T20:16:29+00:00 hourly 0.9 https://trial.medpath.com/news/bf3c0201a79d3d1c/apreo-health-unveils-novel-airway-scaffold-for-severe-emphysema-treatment-at-ats-2025 2025-05-13T20:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/9494c15614149c20/know-biological-s-voli-seizure-monitor-receives-fda-breakthrough-device-designation 2025-05-13T20:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/ec3e318b35726eee/mount-sinai-s-personalized-vaccine-shows-promise-in-bladder-cancer-clinical-trial 2025-05-13T20:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/0e9f2585343dd792/three-year-robust-iii-data-confirms-optilume-drug-coated-balloon-s-durability-for-urethral-strictures 2025-05-13T20:16:03+00:00 hourly 0.9 https://trial.medpath.com/news/17fc372de0063df1/ao-foundation-partners-with-trial-interactive-to-modernize-clinical-trial-management-for-musculoskeletal-research 2025-05-13T20:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/f3baf85857b82062/recipharm-and-plg-form-strategic-alliance-to-streamline-drug-development-and-regulatory-approval 2025-05-13T20:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/86a9eb2f2c08a42a/polynovo-s-novosorb-shows-promising-results-in-type-1-diabetes-wound-treatment-study 2025-05-13T18:41:54+00:00 hourly 0.9 https://trial.medpath.com/news/394c2d5dcf5fb61e/phase-3b-trial-shows-colonoscopic-administration-of-rebyota-effective-for-preventing-recurrent-c-difficile-infection 2025-05-13T18:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/4fbb4977890e4730/affinia-therapeutics-advances-novel-gene-therapy-for-bag3-dilated-cardiomyopathy-with-promising-preclinical-results 2025-05-13T18:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/e974f2619baf83ee/weight-loss-injections-show-promise-for-obese-children-reducing-mealtime-conflicts 2025-05-13T17:39:44+00:00 hourly 0.9 https://trial.medpath.com/news/86f9495fd0bb89d2/exmoor-pharma-and-ku-leuven-form-strategic-alliance-to-accelerate-aav-gene-therapy-development 2025-05-13T17:10:51+00:00 hourly 0.9 https://trial.medpath.com/news/852714829f0e02b3/nrx-pharmaceuticals-acquires-kadima-neuropsychiatry-institute-to-launch-100m-mental-health-clinic-network 2025-05-13T16:45:54+00:00 hourly 0.9 https://trial.medpath.com/news/b1378bbfd7edcc16/algernon-pharmaceuticals-enters-alzheimer-s-diagnostic-market-with-nobrainer-imaging-centers-acquisition 2025-05-13T16:44:24+00:00 hourly 0.9 https://trial.medpath.com/news/b3d1fecc639cdf39/compugen-announces-key-leadership-transition-ceo-cohen-dayag-to-become-executive-chair-as-cso-ophir-takes-helm 2025-05-13T16:44:16+00:00 hourly 0.9 https://trial.medpath.com/news/33dba51eb18594fd/upc-dismisses-sanofi-s-infringement-claim-against-amgen-s-repatha-in-landmark-pcsk9-inhibitor-ruling 2025-05-13T16:43:54+00:00 hourly 0.9 https://trial.medpath.com/news/cb091a81e13110f8/hcw-biologics-novel-fusion-protein-shows-promise-for-revolutionizing-car-t-cell-production 2025-05-13T16:29:08+00:00 hourly 0.9 https://trial.medpath.com/news/3ddf77467b593871/ellipsoid-zone-integrity-linked-to-visual-function-in-geographic-atrophy-patients 2025-05-13T16:28:34+00:00 hourly 0.9 https://trial.medpath.com/news/316681d5a4e9d361/tilt-biotherapeutics-secures-25-6m-series-b-to-advance-novel-oncolytic-virus-therapy-for-ovarian-cancer 2025-05-13T16:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/3e0cde57aa9497e6/landmark-science-launches-specialized-rwe-solutions-to-bridge-biopharma-vendor-gap 2025-05-13T16:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/03e7108e327269c3/hyundai-adm-bio-pivots-strategy-to-focus-on-immunotherapy-combinations-for-cancer-treatment 2025-05-13T16:27:44+00:00 hourly 0.9 https://trial.medpath.com/news/69c389907a777e25/sanyou-bio-and-transrecobio-form-strategic-alliance-to-accelerate-novel-drug-development-in-china 2025-05-13T16:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/fb9264b4104bc70e/takeda-s-adzynma-becomes-first-uk-approved-treatment-for-rare-blood-clotting-disorder-cttp 2025-05-13T16:18:30+00:00 hourly 0.9 https://trial.medpath.com/news/2fa651e5df5e547f/bevacizumab-capecitabine-combination-shows-promise-for-elderly-patients-with-metastatic-colorectal-cancer 2025-05-13T16:18:25+00:00 hourly 0.9 https://trial.medpath.com/news/4a17579ad8709301/myrtelle-to-share-first-year-insights-from-fda-s-start-pilot-program-for-rare-disease-therapies-at-asgct-2025 2025-05-13T16:18:24+00:00 hourly 0.9 https://trial.medpath.com/news/3b35fc1713b8c590/mindera-health-s-mind-px-test-demonstrates-improved-outcomes-in-randomized-psoriasis-trial 2025-05-13T16:18:16+00:00 hourly 0.9 https://trial.medpath.com/news/6b1dd15ac8cac241/prevencio-s-ai-powered-blood-test-for-coronary-artery-disease-receives-fda-breakthrough-device-designation 2025-05-13T16:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/1934389530636181/eligo-bioscience-secures-5m-grant-to-advance-microbiome-based-gene-therapy-for-skin-diseases 2025-05-13T16:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/4b37b66f4e66d243/eur26-2-million-greg-initiative-launches-to-transform-real-world-evidence-practices-across-europe 2025-05-13T16:16:11+00:00 hourly 0.9 https://trial.medpath.com/news/d584dcba8cb8c950/prorx-pharma-and-gatlan-form-strategic-partnership-to-advance-men-s-health-products 2025-05-13T16:16:09+00:00 hourly 0.9 https://trial.medpath.com/news/4f27bc216b61be62/fda-expands-optison-ultrasound-enhancing-agent-approval-for-pediatric-cardiac-imaging 2025-05-13T16:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/e3327d62fb1eda27/olaparib-before-surgery-shows-100-survival-rate-in-brca-mutated-breast-cancer-patients 2025-05-13T16:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/24d956d3008494a0/phasev-secures-50m-series-a-to-transform-clinical-trials-with-ai-platform 2025-05-13T16:15:52+00:00 hourly 0.9 https://trial.medpath.com/news/e651316cab379869/gsk-and-iteos-terminate-tigit-cancer-drug-development-after-phase-2-failure 2025-05-13T16:11:33+00:00 hourly 0.9 https://trial.medpath.com/news/a927dd04a9413af3/atossa-therapeutics-shifts-focus-to-metastatic-breast-cancer-with-z-endoxifen-strengthens-patent-portfolio 2025-05-13T15:10:41+00:00 hourly 0.9 https://trial.medpath.com/news/601f6eb18933a550/indivior-advances-gabab-positive-allosteric-modulator-through-ind-enabling-studies-for-substance-use-disorders 2025-05-13T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/da31284007c8072e/breakthrough-nanotechnology-targeted-liposomes-dramatically-enhance-antifungal-treatment-against-resistant-candida 2025-05-13T13:42:28+00:00 hourly 0.9 https://trial.medpath.com/news/4523f91be5bafa75/axsome-therapeutics-secures-570-million-credit-facility-from-blackstone-to-strengthen-cns-portfolio 2025-05-13T13:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/442b95ccb694e7a6/cns-pharmaceuticals-secures-orphan-drug-designation-for-tpi-287-in-brain-cancer-treatment 2025-05-13T12:37:37+00:00 hourly 0.9 https://trial.medpath.com/news/5c953b19200c59cc/ten-year-aphinity-data-shows-perjeta-based-regimen-reduces-death-risk-by-17-in-her2-positive-early-breast-cancer 2025-05-13T12:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/eb10a89fcd74dd87/astrazeneca-to-present-groundbreaking-respiratory-research-at-ats-2025-conference 2025-05-13T12:36:09+00:00 hourly 0.9 https://trial.medpath.com/news/28657b581456cb4a/ema-approves-moleculin-s-phase-iib-iii-trial-application-for-aml-treatment 2025-05-13T12:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/8fbaae87cb0f47f9/emcutix-and-mantra-pharma-launch-advanced-urea-based-moisturizer-for-hyperkeratotic-skin-conditions 2025-05-13T12:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/04bec9407ec797f0/global-thrombocytopenia-clinical-trials-market-sees-significant-growth-in-2025 2025-05-13T12:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/444285d3b47f8adb/expres2ion-amends-clinical-trial-protocol-to-test-breast-cancer-vaccine-in-combination-with-antibody-drug-conjugates 2025-05-13T12:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/ad5f3d4a379f0a80/long-term-real-world-data-confirms-pitolisant-safety-and-efficacy-in-narcolepsy-patients 2025-05-13T12:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/bf607defc9163a56/iotamotion-expands-robotic-cochlear-implant-technology-internationally-with-swiss-clinical-trial 2025-05-13T11:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/ea00150f28fa8efc/roche-invests-in-new-manufacturing-facility-in-north-carolina-to-expand-biopharmaceutical-production 2025-05-13T10:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/5921b1d69a98c4d5/cepi-invests-2-87-million-in-acm-biolabs-thermostable-mrna-vaccine-delivery-platform 2025-05-13T08:37:14+00:00 hourly 0.9 https://trial.medpath.com/news/77093a330165da2f/irlab-secures-extended-patent-protection-for-parkinson-s-drug-candidate-mesdopetam 2025-05-13T08:36:43+00:00 hourly 0.9 https://trial.medpath.com/news/c7a7bdfb3115ade7/cereno-scientific-reports-promising-phase-iia-results-for-cs1-in-pulmonary-arterial-hypertension 2025-05-13T08:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/a1bf1beff88de2a2/eg-427-showcases-breakthrough-dual-transgene-hsv-1-vector-technology-at-asgct-meeting 2025-05-13T08:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/7f1853b6b3931bd5/azafaros-secures-eur130m-funding-to-advance-nizubaglustat-into-phase-iii-for-rare-lysosomal-storage-disorders 2025-05-13T08:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/6b0046824841c3dc/azafaros-secures-eur132m-series-b-financing-to-advance-rare-lysosomal-storage-disorder-treatments 2025-05-13T08:34:58+00:00 hourly 0.9 https://trial.medpath.com/news/7f8643b6944e571e/immunitybio-settles-10-5m-lawsuit-over-fda-rejection-of-cancer-drug-anktiva 2025-05-13T08:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/101656c3535c40e0/innogen-seeks-100-million-hong-kong-ipo-to-advance-glp-1-pipeline 2025-05-13T08:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/7205e5a47f97982d/abbisko-s-irpagratinib-atezolizumab-combination-shows-promising-results-for-advanced-liver-cancer 2025-05-13T08:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/e0e3b3b79be5f54a/biovica-partners-with-tempus-to-expand-access-to-divitum-tka-blood-test-for-metastatic-breast-cancer-monitoring 2025-05-13T08:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/8354c6428d50ab3c/seastar-medical-reaches-halfway-enrollment-milestone-in-pivotal-neutralize-aki-trial-for-acute-kidney-injury 2025-05-13T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/d8c3e78b086a6a97/university-of-sydney-secures-8-3-million-for-innovative-clinical-trials-in-cancer-and-addiction-treatment 2025-05-13T08:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/39514272704c7610/herantis-pharma-advances-her-096-for-parkinson-s-disease-final-cohort-of-phase-1b-trial-now-underway 2025-05-13T08:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/100ce7b0c6e4aebb/abl-bio-secures-major-platform-deal-with-gsk-eyes-future-acquisition 2025-05-13T08:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/4773aa6b93cb432e/first-oral-treatment-for-deadly-rhodesiense-sleeping-sickness-now-available-in-three-african-countries 2025-05-13T07:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/0dbac62d0fd307d6/axovia-therapeutics-advances-gene-therapy-for-bardet-biedl-syndrome-blindness-with-promising-preclinical-data 2025-05-13T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d9f49d92de9ad63b/royalty-pharma-secures-99-9-shareholder-approval-for-1-1-billion-external-manager-acquisition 2025-05-13T06:39:30+00:00 hourly 0.9 https://trial.medpath.com/news/9985d6e6a10eeb8d/ring-therapeutics-unveils-breakthrough-anellobricks-platform-for-low-cost-gene-therapy-manufacturing 2025-05-13T06:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/7d7672d1c198219a/qiagen-acquires-genoox-for-70-million-to-strengthen-ai-powered-genomic-analysis-capabilities 2025-05-13T05:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/3c0d8fb7d4be6b6f/engeneic-launches-phase-i-iia-trial-of-novel-edv-nanocell-therapy-for-egfr-positive-advanced-cancers 2025-05-13T04:46:05+00:00 hourly 0.9 https://trial.medpath.com/news/8d9856da456f8b9f/innovo-s-novel-immuno-metabolic-drug-shows-promising-safety-profile-in-phase-1-trial 2025-05-13T04:45:36+00:00 hourly 0.9 https://trial.medpath.com/news/593bf648bf5fe2cc/injectable-drug-delivery-market-projected-to-reach-1-14-trillion-by-2029-as-industry-leaders-convene-for-innovation-summit 2025-05-13T03:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/308191aa5b6d8f6e/federal-appeals-court-reopens-crispr-patent-battle-giving-nobel-laureates-new-hope 2025-05-13T03:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/cb808f0d01567477/mayo-clinic-expert-highlights-advancements-and-challenges-in-minimal-residual-disease-detection 2025-05-13T03:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/e1fe7ed4376908fb/experts-emphasize-need-for-patient-centered-value-in-healthcare-research 2025-05-13T03:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/2c83ed7de1dac6b1/nsd2-overexpression-in-multiple-myeloma-may-drive-immune-evasion-new-research-suggests 2025-05-13T02:41:55+00:00 hourly 0.9 https://trial.medpath.com/news/dc61a8bc2d02c6e8/navigating-advanced-endometrial-cancer-treatment-expert-guidance-for-community-oncologists 2025-05-13T02:40:54+00:00 hourly 0.9 https://trial.medpath.com/news/b9a2a2f250233c67/transcon-pth-shows-sustained-4-year-efficacy-in-hypoparathyroidism-patients 2025-05-13T02:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/dd3a59c4098f4c8e/car-t-cell-therapy-emerges-as-promising-strategy-for-glioblastoma-treatment 2025-05-13T02:12:35+00:00 hourly 0.9 https://trial.medpath.com/news/1dda870be75ad09f/stanford-study-reveals-car-t-cell-therapy-may-cause-mild-cognitive-impairment-in-cancer-patients 2025-05-13T01:40:29+00:00 hourly 0.9 https://trial.medpath.com/news/d3dc8494505199a1/federal-circuit-remands-crispr-patent-dispute-to-ptab-in-ongoing-editas-medicine-case 2025-05-13T01:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/894d34487fb812f6/nmd-pharma-presents-preclinical-data-on-clc-1-ion-channel-inhibition-for-musk-myasthenia-gravis-treatment 2025-05-13T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/db73df760fa0567c/syndax-pharmaceuticals-appoints-dr-nicholas-botwood-as-new-r-d-head-and-chief-medical-officer 2025-05-13T00:36:23+00:00 hourly 0.9 https://trial.medpath.com/news/531b6eb3ad91db54/nih-grants-exclusive-license-to-sangam-lifesciences-for-novel-cancer-drug-delivery-platform 2025-05-13T00:35:43+00:00 hourly 0.9 https://trial.medpath.com/news/93845d299ba29d4d/1-25-million-boost-for-novel-prostate-cancer-drug-qed-203-targeting-advanced-disease 2025-05-13T00:35:36+00:00 hourly 0.9 https://trial.medpath.com/news/a8dc36581aa8da23/uk-researchers-begin-clinical-trials-for-novel-african-swine-fever-vaccine 2025-05-13T00:10:53+00:00 hourly 0.9 https://trial.medpath.com/news/68e6f21788ea9ff5/invivyd-initiates-measles-monoclonal-antibody-discovery-program-to-address-critical-treatment-gap 2025-05-13T00:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/c08fc6dff3fec6ec/bright-minds-bmb-101-completely-eliminates-drop-attacks-in-preclinical-sudep-model 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/acbe6d1233ac85bb/next-generation-vaccine-adjuvants-transform-immunotherapy-with-targeted-immune-activation 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cad1e80e26de4b1b/dupilumab-shows-31-greater-likelihood-of-avoiding-negative-outcomes-in-copd-patients-with-type-2-inflammation 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/683e00b22d2c19ee/fda-approves-tzield-as-first-disease-modifying-therapy-for-type-1-diabetes-prevention 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/106c335c34b0484f/moderna-partners-with-ibm-to-advance-mrna-drug-discovery-through-quantum-computing-and-ai 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bf39dd959efea42a/real-world-study-confirms-faricimab-s-efficacy-in-treating-diabetic-macular-edema 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1ab6aad871885682/novel-mpox-nanoparticle-vaccine-shows-superior-protection-in-preclinical-studies 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3738dcdf01727e34/newcastle-university-spin-out-fibrofind-acquired-by-vespa-capital-to-accelerate-fibrosis-drug-development 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3f984ae1ef222569/apyx-medical-receives-fda-clearance-for-ayon-body-contouring-system-first-all-in-one-aesthetic-platform 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/94a46e3972b58747/sl-bio-and-horizon-space-acquisition-ii-corp-announce-merger-to-advance-cancer-immunotherapy-and-regenerative-medicine 2025-05-12T22:41:03+00:00 hourly 0.9 https://trial.medpath.com/news/e98de74d2a75ee88/gop-proposes-912-billion-medicaid-cuts-despite-intra-party-opposition-and-trump-s-protection-pledge 2025-05-12T21:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/81e4c284ea6bd26b/medicaid-unwinding-disrupts-critical-medication-access-for-youth-with-chronic-conditions 2025-05-12T21:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/32fcecb5c6e72563/maternal-cardiometabolic-risk-factors-during-pregnancy-linked-to-higher-blood-pressure-in-children 2025-05-12T21:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/749f4ed45f55d144/study-reveals-elevated-cardiovascular-risks-in-aging-down-syndrome-patients 2025-05-12T21:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/846bb2534281a53d/perceived-stress-significantly-worsens-copd-outcomes-quadruples-exacerbation-risk 2025-05-12T21:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/cdd3bfad7b841b63/first-u-s-patient-successfully-treated-with-advanced-proton-arc-therapy-for-rare-cancer 2025-05-12T21:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/97a3f2994699fa76/researchers-challenge-standard-diagnostic-test-for-primary-aldosteronism-call-for-paradigm-shift-in-hypertension-care 2025-05-12T21:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/5fd5decd58d1b976/second-opinions-for-breast-cancer-patients-minimal-impact-on-treatment-timelines 2025-05-12T21:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/e39fb64efb5e06b9/study-reveals-1-in-10-internal-medicine-physicians-experience-high-burnout-levels 2025-05-12T21:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/964a974a29f6ca24/immunoprecise-s-lensai-platform-achieves-x-ray-crystallography-level-epitope-mapping-accuracy-in-hours 2025-05-12T20:46:15+00:00 hourly 0.9 https://trial.medpath.com/news/c6aa43f600be4705/long-term-lecanemab-treatment-shows-sustained-benefits-in-early-alzheimer-s-disease 2025-05-12T20:42:57+00:00 hourly 0.9 https://trial.medpath.com/news/6f8783e50b127bc7/federal-circuit-revives-uc-s-crispr-patent-claims-orders-re-evaluation-of-gene-editing-breakthrough 2025-05-12T20:42:47+00:00 hourly 0.9 https://trial.medpath.com/news/331ec7369c88b214/ut-southwestern-breaks-ground-on-177m-radiation-oncology-campus-in-fort-worth 2025-05-12T20:41:35+00:00 hourly 0.9 https://trial.medpath.com/news/ac8158f5695eabb2/piramal-pharma-commits-90-million-to-expand-us-manufacturing-facilities-amid-reshoring-trend 2025-05-12T20:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/627381207d067774/fda-clears-united-imaging-s-uangio-aviva-first-interventional-x-ray-system-with-voice-control 2025-05-12T20:12:45+00:00 hourly 0.9 https://trial.medpath.com/news/280bc9630d305ef8/pharma-vc-investments-reach-6-5-billion-in-q1-2025-with-oncology-leading-the-pack 2025-05-12T19:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/c64719cc29d3b113/caris-life-sciences-pioneers-met-ihc-testing-for-non-squamous-nsclc-patients 2025-05-12T18:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/b809965611108ca1/marvel-biosciences-raises-1-02-million-to-advance-novel-neurological-drug-mb-204 2025-05-12T18:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/e797b6eb1a71a304/regeneron-secures-fda-approval-for-bcma-targeted-bispecific-antibody-in-multiple-myeloma 2025-05-12T17:02:04+00:00 hourly 0.9 https://trial.medpath.com/news/4fe9da62f28be84b/aranscia-acquires-spesana-to-enhance-precision-medicine-workflow-solutions 2025-05-12T16:47:15+00:00 hourly 0.9 https://trial.medpath.com/news/bea13ee8793538f8/secarna-pharmaceuticals-and-curie-bio-portfolio-company-form-strategic-alliance-to-develop-novel-oligonucleotide-therapeutics 2025-05-12T16:45:23+00:00 hourly 0.9 https://trial.medpath.com/news/5c95079f59f99995/roche-invests-300-million-in-new-shanghai-biologics-manufacturing-facility 2025-05-12T16:45:21+00:00 hourly 0.9 https://trial.medpath.com/news/3a5a677feda0cadd/n4-pharma-reports-positive-results-from-first-in-vivo-study-of-nuvec-r-for-inflammatory-bowel-disease 2025-05-12T16:44:43+00:00 hourly 0.9 https://trial.medpath.com/news/f8dfd07e1b2068cf/esperion-secures-patent-protection-for-nexletol-until-2040-through-settlement-with-micro-labs 2025-05-12T16:44:37+00:00 hourly 0.9 https://trial.medpath.com/news/78feb73dbb264066/synact-pharma-secures-extended-us-patent-protection-for-resomelagon-combination-therapy-until-2042 2025-05-12T16:44:34+00:00 hourly 0.9 https://trial.medpath.com/news/27b909401fd6b47e/orthotrophix-launches-phase-2b-trial-of-tpx-100-for-knee-osteoarthritis-with-disease-modifying-potential 2025-05-12T16:43:10+00:00 hourly 0.9 https://trial.medpath.com/news/fa6111d56287aa7e/ensysce-biosciences-strengthens-regulatory-team-ahead-of-critical-phase-3-trials-and-nda-submission 2025-05-12T16:42:28+00:00 hourly 0.9 https://trial.medpath.com/news/a07a187cd2d17346/bioxytran-achieves-critical-milestone-in-prolectin-m-antiviral-development 2025-05-12T16:42:05+00:00 hourly 0.9 https://trial.medpath.com/news/b02e1216cb937a29/fda-clears-ind-for-mavrix-bio-s-gene-therapy-for-angelman-syndrome-first-in-human-trial-to-begin-in-2025 2025-05-12T16:41:57+00:00 hourly 0.9 https://trial.medpath.com/news/43711e5b972cfb00/quidditas-secures-eur2-62m-to-advance-revolutionary-genome-editing-technology-for-rare-disease-treatment 2025-05-12T16:41:55+00:00 hourly 0.9 https://trial.medpath.com/news/388b7464b0fdd779/fda-clears-capsida-s-revolutionary-iv-gene-therapy-for-stxbp1-dee-first-to-cross-blood-brain-barrier 2025-05-12T16:41:23+00:00 hourly 0.9 https://trial.medpath.com/news/aee1bb7fe8c3bc54/omeros-restructures-80-5-million-in-debt-significantly-reducing-near-term-financial-obligations 2025-05-12T16:40:53+00:00 hourly 0.9 https://trial.medpath.com/news/5dd8d739b05e0069/fda-clears-ind-for-ensoma-s-first-in-class-in-vivo-gene-therapy-for-x-linked-chronic-granulomatous-disease 2025-05-12T16:40:52+00:00 hourly 0.9 https://trial.medpath.com/news/894a9e6325334cd9/andelyn-biosciences-delivers-breakthrough-gene-therapy-for-ultra-rare-nedamss-disease-in-record-time 2025-05-12T16:40:50+00:00 hourly 0.9 https://trial.medpath.com/news/0e49aa45d4970831/car-t-cell-therapy-funding-surges-to-141-2-billion-as-industry-expands-globally 2025-05-12T16:40:45+00:00 hourly 0.9 https://trial.medpath.com/news/f88a6a47969ceb7f/igc-pharma-s-alzheimer-s-drug-igc-ad1-passes-critical-genetic-safety-test 2025-05-12T16:40:11+00:00 hourly 0.9 https://trial.medpath.com/news/1beddb141476ce66/fda-approves-first-targeted-therapy-for-igg4-related-disease-amgen-s-uplizna 2025-05-12T16:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/57998c549ac6fff3/curaleaf-international-secures-eu-medical-device-certification-for-pioneering-cannabis-inhalation-technology 2025-05-12T16:17:07+00:00 hourly 0.9 https://trial.medpath.com/news/6eee584811ffaa65/genentech-to-invest-700-million-in-new-north-carolina-manufacturing-facility-creating-400-high-paying-jobs 2025-05-12T16:15:58+00:00 hourly 0.9 https://trial.medpath.com/news/a8d21237a7068cbb/nextgen-jane-secures-2-2m-nih-grant-to-validate-non-invasive-endometriosis-diagnostic 2025-05-12T16:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/cb64f8348d2cc813/grit-biotechnology-to-present-breakthrough-immunotherapy-advances-at-asgct-2025 2025-05-12T16:15:36+00:00 hourly 0.9 https://trial.medpath.com/news/764d6f7f88bd31af/true-indicating-secures-fda-clearance-for-cspn-15-steam-sterilization-monitoring-device 2025-05-12T16:15:21+00:00 hourly 0.9 https://trial.medpath.com/news/d1cc6fd7519dacc3/vgxi-s-successful-fda-inspection-leads-to-client-s-bla-approval-strengthening-position-in-plasmid-dna-manufacturing 2025-05-12T16:15:17+00:00 hourly 0.9 https://trial.medpath.com/news/98419e7758b91c3a/inbrain-pharma-secures-eur1-8-million-to-industrialize-anaerobic-dopamine-production-for-advanced-parkinson-s-disease 2025-05-12T16:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/36b37240917bf138/ubrogepant-shows-promise-in-treating-migraine-prodromal-symptoms-in-phase-iii-trial 2025-05-12T16:13:41+00:00 hourly 0.9 https://trial.medpath.com/news/2e3e2762992eadeb/36-month-results-of-opregen-cell-therapy-for-geographic-atrophy-to-be-presented-at-cts-2025 2025-05-12T16:13:37+00:00 hourly 0.9 https://trial.medpath.com/news/867ef390fbb34d62/fda-approved-alzheimer-s-drug-lecanemab-shows-manageable-safety-profile-in-real-world-setting 2025-05-12T16:13:32+00:00 hourly 0.9 https://trial.medpath.com/news/952b248a2d111f31/intrepid-labs-emerges-from-stealth-with-ai-powered-platform-to-revolutionize-drug-formulation 2025-05-12T14:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/ab708089f42545a4/veradigm-deploys-ai-to-extract-real-world-insights-on-glp-1-medications-from-ehr-data 2025-05-12T14:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/844cd0db7f091ec9/aura-and-life360-form-25-million-strategic-partnership-for-family-safety-solutions 2025-05-12T14:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/5cae2fc438629406/moderna-s-mrna-1273-covid-19-vaccine-shows-promise-in-phase-1-trial-advances-to-phase-3-testing 2025-05-12T12:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/81dee6c484a67c1b/india-rejects-uk-s-data-exclusivity-demand-to-protect-25-billion-generic-drug-industry 2025-05-12T12:36:12+00:00 hourly 0.9 https://trial.medpath.com/news/16d2f9c9233f992a/chong-kun-dang-invests-w10-billion-in-abclon-to-advance-car-t-and-antibody-therapies 2025-05-12T12:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/a6cfee8583ef568d/cytomx-s-cx-2051-shows-promising-28-response-rate-in-advanced-colorectal-cancer-phase-1-trial 2025-05-12T12:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/cc798513e20d72c3/eli-lilly-and-purdue-university-forge-250-million-partnership-to-accelerate-pharmaceutical-innovation 2025-05-12T12:34:27+00:00 hourly 0.9 https://trial.medpath.com/news/31287f2c542c4fcb/new-transcatheter-tricuspid-valve-treatments-offer-hope-for-high-risk-cardiac-patients 2025-05-12T12:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/7318b199a63a76b8/thermosome-s-the001-receives-fda-orphan-drug-designation-for-soft-tissue-sarcoma-treatment 2025-05-12T12:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/902ccabbc6efd8da/orca-bio-appoints-co-founder-nate-fernhoff-as-ceo-ahead-of-2025-bla-submission-for-orca-t 2025-05-12T11:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/4235a547d0efc474/zynex-submits-fda-application-for-nico-revolutionary-laser-pulse-oximeter-addresses-racial-bias-in-patient-monitoring 2025-05-12T09:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/32157f74f6dfba8f/alligator-bioscience-to-present-biomarker-data-from-promising-pancreatic-cancer-trial-at-asco-2025 2025-05-12T08:40:50+00:00 hourly 0.9 https://trial.medpath.com/news/a8d72338b9ecf9b8/novo-nordisk-s-once-weekly-sogroya-shows-efficacy-in-children-with-growth-disorders-in-phase-3-trial 2025-05-12T08:40:07+00:00 hourly 0.9 https://trial.medpath.com/news/9ecb9c7d9fa5f81a/astrazeneca-s-trixeo-aerosphere-becomes-first-inhaled-respiratory-medicine-with-near-zero-climate-impact-propellant 2025-05-12T08:39:50+00:00 hourly 0.9 https://trial.medpath.com/news/bd39668dd1b899c7/leucid-bio-doses-first-patient-in-aerial-trial-of-novel-nkg2d-car-t-therapy-for-solid-tumors 2025-05-12T08:39:47+00:00 hourly 0.9 https://trial.medpath.com/news/1c6a95791b0f740b/valirx-expands-precision-oncology-partnership-with-dominion-biotech-through-predictrx-platform-licensing 2025-05-12T08:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/e1b3b23a08cb31ee/metis-pharmaceuticals-plans-200-million-hong-kong-ipo-to-advance-ai-driven-drug-development 2025-05-12T08:39:10+00:00 hourly 0.9 https://trial.medpath.com/news/83ec83dcd7f82177/fda-approves-aqilion-s-ind-application-for-aq280-in-eosinophilic-esophagitis-treatment 2025-05-12T08:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/8168ca4e0a77cb3f/vuno-s-ai-powered-cardiac-arrest-prediction-system-secures-ce-mdr-and-ukca-certifications 2025-05-12T08:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/f80d04da5d677fc9/synthego-launches-gmp-spcas9-to-streamline-crispr-therapeutic-development 2025-05-12T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/86e15d9fe3fa773b/agenus-reports-breakthrough-response-rates-for-bot-bal-combination-in-cold-tumors 2025-05-12T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/329e050c3e55ff78/former-j-j-executive-herwig-janssen-appointed-chairman-of-tryptamine-therapeutics-as-company-advances-psilocin-based-clinical-programs 2025-05-12T04:40:27+00:00 hourly 0.9 https://trial.medpath.com/news/e95d9ee47daf656a/radiopharm-theranostics-advances-phase-1-trial-of-pd-l1-targeting-radiotherapeutic-for-advanced-cancers 2025-05-12T04:39:42+00:00 hourly 0.9 https://trial.medpath.com/news/6b629493794c98d8/carsgen-s-allogeneic-bcma-car-t-shows-promising-safety-and-efficacy-in-relapsed-refractory-multiple-myeloma 2025-05-12T04:38:59+00:00 hourly 0.9 https://trial.medpath.com/news/7e8b1d71ebdd7abd/innocare-s-mesutoclax-receives-breakthrough-therapy-designation-in-china-for-lymphoma-treatment 2025-05-12T04:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/cf1697ecd016816e/nanoscope-therapeutics-showcases-mco-010-optogenetic-therapy-data-at-asgct-2025 2025-05-12T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f2354990a0f96483/weight-loss-injections-show-promising-anti-cancer-effects-beyond-weight-reduction 2025-05-12T02:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/1eef8d53834319d3/denosumab-shows-immunomodulatory-effects-in-her2-negative-early-breast-cancer 2025-05-12T00:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/8490caa355a4458c/wehi-3773-small-molecule-shows-promise-for-blocking-cell-death-in-neurodegenerative-diseases 2025-05-12T00:34:20+00:00 hourly 0.9 https://trial.medpath.com/news/a9c2ea307b2b3248/united-healthcare-approves-reimbursement-for-helius-medical-s-pons-device-for-ms-patients 2025-05-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/99c885fea28ea834/tobin-scientific-secures-65m-investment-to-expand-life-sciences-infrastructure-and-services 2025-05-11T20:39:55+00:00 hourly 0.9 https://trial.medpath.com/news/2dcd4591c0c1c56f/saudi-arabia-seeks-to-localize-insulin-and-glp-1-production-through-novo-nordisk-partnership 2025-05-11T20:39:43+00:00 hourly 0.9 https://trial.medpath.com/news/96b8b4a2083f9026/astrazeneca-acquires-esobiotec-for-1-billion-revolutionary-in-vivo-car-t-technology-to-transform-cancer-treatment 2025-05-11T20:39:25+00:00 hourly 0.9 https://trial.medpath.com/news/5f55cc3184d48248/type-2-diabetes-significantly-increases-risk-of-mash-progression-to-cirrhosis-new-target-rwe-study-reveals 2025-05-11T17:36:25+00:00 hourly 0.9 https://trial.medpath.com/news/ce0c2851eed94c3e/lorlatinib-shows-impressive-5-year-pfs-results-in-alk-positive-advanced-nsclc 2025-05-11T16:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/420a3329bcb4bb2e/inductive-bio-secures-25m-series-a-to-revolutionize-small-molecule-drug-discovery-with-ai 2025-05-11T16:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/c03b78f2113f6918/tfox-regimen-shows-superior-efficacy-over-folfox-in-advanced-her2-negative-gastric-cancer 2025-05-11T16:38:34+00:00 hourly 0.9 https://trial.medpath.com/news/417d10829b944d0b/givinostat-shows-promise-for-duchenne-muscular-dystrophy-as-families-push-for-broader-access 2025-05-11T16:10:30+00:00 hourly 0.9 https://trial.medpath.com/news/55ce3596f8698e62/innovative-hydrogel-technologies-transform-chronic-wound-treatment-with-enhanced-healing-properties 2025-05-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/37ad781c7ec19ddd/glass-house-brands-partners-with-uc-berkeley-for-groundbreaking-hemp-research-initiative 2025-05-11T12:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/83d02160d62a998b/abcellera-s-abcl575-shows-promise-for-atopic-dermatitis-with-extended-half-life-in-preclinical-studies 2025-05-11T12:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/dd6ac865b74709ac/sivec-s-bactpac-platform-engineered-bacteria-redefining-targeted-drug-delivery-for-cancer-and-beyond 2025-05-11T08:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/f7ce42486a1a9f08/vietnam-signs-agreement-to-access-russia-s-potential-mrna-cancer-vaccine 2025-05-11T04:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/8bf3894981032d25/omada-health-files-for-ipo-showcasing-strong-growth-in-virtual-chronic-care-market 2025-05-11T03:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/09db6d26875ed395/biocon-announces-150-million-capital-expenditure-plan-amid-strong-q4-performance 2025-05-11T00:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/aa777fbe8fcc5564/amneal-and-apiject-partner-to-expand-us-based-sterile-injectable-manufacturing-with-advanced-bfs-technology 2025-05-11T00:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/836c4fde8ed3e999/kouper-emerges-from-stealth-with-10m-to-transform-hospital-discharge-care-transitions 2025-05-11T00:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/c08faf624aafba58/johns-hopkins-study-identifies-key-immune-defects-limiting-pancreatic-cancer-immunotherapy-response 2025-05-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/18c9d6256e626763/cytel-and-nested-knowledge-partner-to-revolutionize-ai-enhanced-systematic-literature-reviews-for-healthcare-economics 2025-05-10T23:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/0cf6339dbf1c4440/adma-biologics-secures-fda-clearance-for-yield-enhancement-process-poised-for-margin-expansion-in-2026 2025-05-10T21:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/b4415a4b02622831/nanyang-biologics-and-precisya-global-form-strategic-alliance-to-advance-ai-driven-natural-compound-discovery 2025-05-10T21:11:38+00:00 hourly 0.9 https://trial.medpath.com/news/0f8229e57329e95b/cdsco-approves-novartis-protocol-amendment-for-iptacopan-study-in-rare-kidney-disorders 2025-05-10T20:39:28+00:00 hourly 0.9 https://trial.medpath.com/news/f9bbdd125423beef/eyp-1901-shows-promising-results-in-verona-trial-for-diabetic-macular-edema 2025-05-10T20:10:20+00:00 hourly 0.9 https://trial.medpath.com/news/af3b5469002736aa/hku-researchers-develop-breakthrough-needle-free-flu-vaccine-with-broader-protection 2025-05-10T20:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/be1d3dddd8f805e5/clemson-researchers-test-existing-drugs-for-sanfilippo-syndrome-using-fruit-fly-models 2025-05-10T18:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/156e38d138217d77/healthy-extracts-secures-exclusive-rights-to-innovative-nutrient-infused-straw-technology 2025-05-10T17:41:23+00:00 hourly 0.9 https://trial.medpath.com/news/1bce13e3074c425b/ai-designed-dna-successfully-controls-gene-expression-in-mammalian-cells-for-first-time 2025-05-10T17:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/90a9585d3492d035/phase-3-ecog-acrin-ea4151-trial-evaluates-necessity-of-auto-hct-in-modern-mcl-treatment 2025-05-10T16:35:48+00:00 hourly 0.9 https://trial.medpath.com/news/f08ef4a5a4987f9e/helios-trial-shows-promise-otx-tki-demonstrates-positive-results-for-diabetic-retinopathy-treatment 2025-05-10T16:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/4215c969eda82cea/skyline-therapeutics-to-present-novel-optogenetic-gene-therapy-for-retinitis-pigmentosa-at-asgct-2025 2025-05-10T16:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/beef9eeb59554506/lithuanian-firm-delta-biosciences-to-launch-pioneering-space-pharmaceutical-stability-study-on-iss 2025-05-10T16:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/bc4ed2862772cfdf/hawaii-secures-700-million-settlement-from-bristol-myers-squibb-and-sanofi-over-plavix-efficacy-in-diverse-populations 2025-05-10T15:11:05+00:00 hourly 0.9 https://trial.medpath.com/news/567fcb9685d6606d/scg101-shows-dual-antiviral-and-antitumor-effects-in-hbv-related-liver-cancer-trial 2025-05-10T15:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/f20173987909bd22/johnson-johnson-medtech-partners-with-qure-ai-to-advance-ai-powered-lung-cancer-detection-in-india 2025-05-10T13:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/8c3010f330498c2e/trailhead-biosystems-secures-20m-to-advance-ipsc-technology-for-drug-discovery-and-regenerative-medicine 2025-05-10T12:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/c31468a8b0e459ab/thirona-and-copd-foundation-launch-major-ai-study-to-transform-copd-treatment 2025-05-10T12:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/e2cfa2c56a7a6071/aflibercept-8-mg-shows-extended-dosing-intervals-in-real-world-namd-treatment 2025-05-10T09:04:54+00:00 hourly 0.9